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Ovarian cancer is the most lethal gynaecologic malignancy, with a high mortality rate that is associated 
with the difficulty of treating the disease. This is due to the typical onset of symptoms when the 
disease is at a fairly advanced stage. Improved treatment strategies are required to improve longevity 
in patients.  Recently polyphenols, secondary metabolites in plants, have aroused interest with respect 
to the treatment of cancer. The purpose of this study was to investigate the effect of two polyphenols, 
resveratrol and its derivative pterostilbene, on cell metabolism and proliferation in two ovarian cancer 
cell lines, OVCAR-5 and SKOV-3 that were grown in a three dimensional culture. The proteins VEGF, 
AKT, EGFR, HER2, cyclin D2 and PCNA were investigated to identify any possible changes to signalling 
pathways following exposure to the polyphenols. Both resveratrol and pterostilbene affected spheroid 
metabolism and proliferation in a dose- and cell line-dependant manner. Vascular endothelial growth 
factor and expression of the various proteins were affected following treatment. This study 
demonstrates that resveratrol and pterostilbene are capable of down regulating the cell metabolism 
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Chapter 1: Introduction 
1.1 . Overview 
Ovarian cancer is the most lethal gynaecologic malignancy and most commonly originates at 
the surface epithelium of the ovary. Globally, this is the 7th most common diagnosed cancer 
with 6.3 per 100,000 women being diagnosed. This statistic increases in more resource rich 
countries to being the 5th most diagnosed cancer with 9.3 cases per 100,000 women (Prat 
2014). Overall, ovarian cancer results in approximately 225,000 women being diagnosed and 
approximately 140,000 deaths globally per year (Banerjee and Kaye 2013). 
Current treatment options include surgery and chemotherapy. These can be combined as a 
reduction in the tumour size can potentially increase the effectiveness and diffusion 
capabilities of chemotherapeutic drugs, in addition to decreasing the chance of drug 
resistance by the cells (van der Burg, van Lent et al. 1995). Treatment with chemotherapy has 
improved throughout the years with attempts to decrease drug toxicity while increasing 
effectiveness (Agarwal and Kaye 2003). The use of surgery and chemotherapy has now 
surpassed radiotherapy as the common treatment option due to the limitations which 
occurred with radiotherapy. However, due to increasing resistance by the cells, these 
treatment options are limited and therefore further therapies need to be determined. 
The use of natural products for the treatment of cancer has been of interest for many 
decades, however of more recent interest are polyphenols due to their ability to inhibit cell 
proliferation (Manach, Scalbert et al. 2004, Han, Shen et al. 2007). Of particular interest are 
two stilbenes, resveratrol and pterostilbene. These have previously been shown to affect 
various cancers types, but there are limited studies focussing on their effects on ovarian 
cancer (McCormack and McFadden 2012, Stakleff, Sloan et al. 2012) 
1.2. Cancer 
The written history of cancer is thought to date back as early as 3000BC, where the first known 
surviving manuscript described the origin and potential treatment of this disease.  Since then 
there have been hundreds of distinct types of cancer and cancerous subgroups described, and 
cancer is the second largest cause of death globally (Aggarwal, Danda et al. 2009). In 2012, 14 
million people were diagnosed and 8.2 million people died from some form of cancer (World 
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Health Organisation). These statistics have been relatively static throughout the years, 
however it is predicted this will increase to 17 million deaths and 27 million diagnoses globally 
by the year 2030 due to the growing population and increasing longevity. (Aggarwal, Danda 
et al. 2009).  
Five to ten percent of cancer cases are caused directly by genetic factors such as inherited 
genes containing the cancerous defects or elevated levels of hormone production. The 
remaining 90-95% are influenced by diet and lifestyle choices including smoking, alcohol 
consumption or environmental pollutants which lead to cancerous genetic mutations. 
Statistics indicate that between 30-35% of cancer is associated with diet (Anand, 
Kunnumakara et al. 2008). 
Cancer forms due to uncontrollable cell growth caused by a loss of the balance between cell 
proliferation and cell death via apoptosis or autophagocytosis. The transition from normal 
cells to cancerous cells occurs in a two-step process: (1) initiation; during which the DNA 
becomes damaged, creating a pre-neoplastic cell and (2) promotion; during which the pre-
neoplastic cell is promoted by growth factors or hormones which allow tumour growth 
(Barnard 2004). Abnormal cell growth is enabled by shutting off the cells regulation, either by 
the alteration of proteins or deregulation of signalling pathways. Proteins and pathways 
affected vary depending on the type of cancer.  
Six important changes are thought to be involved in the majority of cancer types which 
override the cells defence mechanisms. (1) The ability to be self-sufficient for growth signals. 
Proliferation in normal cells is controlled by mitogenic growth signals. In many cancers these 
growth signals are mimicked, either by the alteration of extracellular growth signals, 
transcellular transducers or cellular circuits that are responsible for translating growth signals. 
Overall this allows the cancer to be independent from its environment for proliferation. (2) 
The cancer must become insensitive to the antigrowth signals that are produced by normal 
cells to block cellular proliferation. Cells achieve this by altering the pathways responsible for 
producing anti-proliferative signals. (3) Cancer cells must acquire the ability to evade 
apoptosis, which is typically used to remove abnormal cells. This occurs via a mutation in a 
signalling pathway responsible for the transmission of anti-apoptotic signals. In many cases 
the p53 tumour suppressor protein is mutated. (4) The ability to have endless replication of 
the cells.  The hallmarks allowing proliferation to occur and form cancerous cells is limited by 
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the amount of replications that can occur by the cells. By overcoming this limitation, the cells 
are capable of continuously replicating, resulting in larger tumours and the potential to 
spread further throughout the body. (5) Angiogenesis, or the ability to form new blood 
vessels. In normal cells this is controlled by inducers and inhibitors, however in cancer this 
control can be lost and the balance must favour the inducers, a process achieved by 
alterations in gene transcription. (6) To enable relocation of the cancer cells to a nutrient rich 
environment they must acquire the ability to invade other locations in the body via 
detachment from initial tumour, and then attachment at the new location  (Hanahan and 
Weinberg 2000).  
1.2.1. The Female Reproductive System and Ovarian Cancer  
The female reproductive system is comprised of two ovaries, two fallopian tubes, a uterus 
and a vagina (Figure 1.1). The ovaries are responsible for producing many of the female 
hormones and the production of eggs. The eggs travel via the fallopian tubes to the uterus 
where they become fertilised. 
The ovaries, which are composed of germ cells and somatic cells, are located near the lateral 
wall of the pelvic cavity and are responsible for controlling ovulation and the maturation of 
eggs through the regulation of hormone levels. Early in the menstrual cycle, follicle growth is 
increased to allow the release of hormones that are important for the continuation of the 
menstrual cycle. At the start of the cycle, the gonadotropin-releasing hormone level pulsates 
at a low frequency, stimulating an increase in the amount of the follicle-stimulating hormone 
being secreted from the anterior pituitary gland, and thus an increase in follicle growth. 
Halfway through the menstrual cycle the level of pulsing of the gonadotropin-releasing 
hormone increases in frequency, shutting off follicle growth and increasing the amount of 
luteinizing hormone that is released from the anterior pituitary gland, resulting in ovulation 
and maturation of the eggs. When the control of this cycle is lost, various types of cancer can 





























Figure 1.1. An overview of the female reproductive system. The ovaries are two small, oval 
shape organs which are responsible for the production of female hormones and reproductive 
eggs. The ovaries are connected to the uterus by the fallopian tube.  




A lack of early symptoms and markers make ovarian cancer difficult to detect. 70% of 
diagnoses occur at an advanced stage and in only 30% of these cases will the patient survive 
5 years, a factor that is associated with the high mortality rates for this disease (Cho and Shih 
2009, Weiderpass and Labrèche 2012). 
There are three classifications of ovarian cancer: (1) epithelial tumours: these initially form 
on the surface of the ovary, (2) stromal tumours: these originate in the interior of the ovary 
and (3) germ cell tumours: these form via embryological differentiation (Figure 1.2) (Ang, 
Chan et al. 2011). The majority (90%) of ovarian cancers are epithelial. The epithelial ovarian 
cancers are further subdivided into; mucinous, endometroid, clear cell and the most common, 
serous carcinoma, on the basis of their histology and morphology. Cancers that originate in 
the stromal and the germ cell account for 5% and <5% of cases respectively (Cho and Shih 
2009, Weiderpass and Labrèche 2012). Tumour growth is classified into grades, depending on 
the amount of growth that has occurred. Low grade tumours, classified as either grade 1 or 
2, have at most 50% solid growth. In contrast, a high grade tumour (classified as grades 3 and 
4) has at least 50% solid growth (Cho and Shih 2009). 
Furthermore, ovarian tumours can be further categorised by type, based on their histology. 
Type I include low grade serous carcinoma, endometroid, mucinous and clear cell carcinomas. 
Typically, these are slower growing and confined to either one or both ovaries when 
diagnosed. Low grade tumours occur via somatic mutations in several genes and are relatively 
stable. Type II tumours are highly aggressive with rapid growth. Typically at diagnosis these 
tumours will have extended out of the ovaries and have become advanced and unstable. 
These include high grade serous carcinomas, high grade endometroid and clear cell 
carcinomas. Somatic mutations are rarely associated with Type II tumours, instead a mutation 
in the cell growth control gene, is TP53, is believed to be largely responsible (Kurman, 

























Figure 1.2. Illustration of different locations of cancer cells within the ovary. The surface 
epithelial cells occur on the edge of the ovary while the germ cells and sex-cord-stroma cells 
are within the ovary. The germ cell cancers form through embryological differentiation while 
the sex-cord-stromal cancers form from the interior of the ovary 
Image adapted from http://d3jonline.tripod.com/24-Reproduction/pathology_of_ovary_2.gif 
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Only five to ten percent of ovarian cancer cases are associated with genetic inheritance. Of 
these, mutations in two tumour suppressing genes, BRCA1 and  BRCA2, are responsible for 
the majority of familial early onset cases and the inheritance of genes causing a genetic 
predisposition to this disease (Ludwig, Chapman et al. 1997, Kurman, Visvanathan et al. 2008). 
Mutations affecting the BRCA1 gene results in a dysfunctional DNA damage repair pathway, 
ultimately causing an effect on the cell cycles regulation and thus effects proliferation. This 
subsequently can result in the transfer of the mutated genes to subsequent generations 
(Chen, Silver et al. 1998, Hilton, Geisler et al. 2002). The mutated BRCA1 and BRCA2 genes 
both result in truncated protein products in germline and somatic mutations. Those occurring 
in the germline were found to have a much larger occurrence percentage (38%) in women 
with a family history of either BRCA1 or BRCA2 than those without, and somatic mutations 
have a larger percentage of women without family history being diagnosed (76%), suggesting 
some of these genes are hereditary (Hilton, Geisler et al. 2002). 
Several additional genes have been associated with ovarian cancer, specifically BRAF, KRAS 
and TP53. If either BRAF or KRAS are mutated in Type I carcinomas the other will function 
normally, suggesting both are involved in the same pathway. The associated RAS-RAF-MEK-
ERK pathway is responsible for regulating cell growth and proliferation through a RAS-
activated protein kinase cascade. The mutation of either BRAF or KRAS activates the mitogen-
activated protein kinase/signal-regulated protein kinase (MAPK/ERK) which is downstream of 
these genes, resulting in the activation of cell growth, proliferation, and ovarian tumour 
formation. Both KRAS and BRAF are observed in more than half of serous carcinomas. P53 is 
a tumour suppressor protein responsible for regulating the cell cycle and monitoring cell 
stability. If DNA damage is present, it prevents the cell cycle continuing. Therefore a mutation 
in the gene for P53, TP53, would cause this control to be lost, resulting in an increase in 
proliferative rates and the formation of tumours. This is one of the most commonly mutated 
genes in cancer, including ovarian cancer, yet it rarely occurs in Type I tumours (Greenblatt, 






1.3. Cell Cycle and Proliferation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
Regulation of the cell cycle is essential in all parts of the body to ensure cells divide at the 
correct time. Additionally this regulation allows the repair of DNA before completion of the 
cycle. It has been suggested that the risk of developing ovarian cancer increases when the 
ovulation cycle is not inhibited, as there is a rupture in the epithelial cells during each 
ovulation. This damage then requires several rounds of cell division to repair the wound, 
increasing the possibility of incorrect cell division and growth. To ensure these cells are 
repaired correctly after damage, a cell cycle repair mechanism controlled by cell cycle 
checkpoints is required and completed. Initiation of checkpoints later in the cycle is 
dependent on completion of prior checkpoints, to ensure there is no DNA damage. During 
cancer formation, these checkpoints are disrupted so recognition of damaged DNA cannot 
occur, resulting in proliferation of abnormal cells (Godwin, Testa et al. 1992). 
The cell cycle is comprised of 5 different phases; the growth phases G0, G1, and G2 which are 
additionally responsible for checking the completion of the DNA replication prior to the cell 
finalising replication. The active phases are the DNA synthesis phase (S-phase), which is 
responsible for duplicating the genome and DNA synthesis, and the mitotic phase (M-phase) 
which is where mitosis occurs. Each phase is regulated with different control points. 
Checkpoints between the different phases are responsible for allowing the continuation of 
the cycle into the next phase. The cycle starts at the G0 stage, which is quiescent and relies on 
signals from external stimuli, such as growth signals or mitogens to move it past the G1 
checkpoint and thus begin the cell cycle. The G1 stage of the cycle is the gap phase between 
the M-phase (which typically takes 1-2 hours to complete) and the S-phase (which typically 
takes 2-4 hours to complete). Replication of the cytoplasmic organelles and cell growth occurs 
in the G1 phase, which typically takes 12-96 hours to complete. The shift to the S-phase is 
controlled at the G1/S checkpoint. Following the 2-4 hours in the G2-phase, the final 
checkpoint occurs, allowing transition from G2-phase to the M-phase, where the cell cycle is 
completed (Figure 1.3) (Israels and Israels 2000). The control of these mechanisms in 
mammalian cells is through the association of serine/threonine kinases, known as cyclin 
dependant kinases (CDKs), which act as a catalytic partner to the regulatory unit cyclin. The 
interaction between these different cyclins (specifically D and E) and kinases (CDK4, CDK6, 
and CDK2) result in phosphorylation of the retinoblastoma tumour suppressor protein, and 
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are required for movement through the cell cycle. The loss of cell regulation and changes in 
the expression levels of these cyclins or CDKs contribute to cancer pathogenesis and 


































Figure 1.3. The cell cycle. This cycle consists of several checkpoints at different stages of 
the cycle, responsible for checking for, and maintaining the correct division of cells.  G0 is 
the start of the cell cycle. After completing the M-phase the cycle is complete. Cyclins and 
cyclin dependant kinases (CDKs) interactions control these mechanisms and differ at the 





Ovarian cancer can spread, either by moving directly to a nearby organ such as the colon or 
the bladder, or by detaching from the tumour and moving via intraperitoneal dissemination. 
Most commonly, intraperitoneal dissemination occurs, which allows part of the primary 
tumour to dissociate and move through the peritoneum via the ascetic fluid until it arrives at 
a new location, which is generally in the abdominal cavity. This usually occurs early in ovarian 
cancer and is probably the reason few cases are diagnosed when the cancer is restricted to 
the ovaries (Lengyel 2010, Nakayama, Nakayama et al. 2012).  
The epithelial cells which form the outer layer of the spheroid and which interact with the 
basement membrane undergo an epithelial-to-mesenchymal (EMT) transformation that 
causes the inter-cellular adhesions between the cancer cells to loosen, resulting in 
detachment from the primary tumour. The mesenchymal cells are essential for metastasis 
because they have an increased migratory ability, are more resistant to apoptosis compared 
to epithelial cells and can increase the production of extracellular matrix (ECM) components 
(Kalluri and Weinberg 2009). During the transition, the E-cadherin holding the cells together 
is lost which allows the cancer cells to become motile and acquire mesenchymal properties 
(Lengyel 2010). When the cells dissociate from the primary ECM, individual cells and/or cell 
clusters (spheroids) must overcome apoptotic control, which they do by overexpressing 
RAB25, which is resistant to apoptosis, enabling movement to the peritoneum or omentum 
via the peritoneal fluid (Figure 1.4) (Shield, Ackland et al. 2009, Nakayama, Nakayama et al. 
2012). 
When the cancerous cells come into contact with the peritoneum, an interaction occurs 
between the cancer cells and the mesothelial cells though cadherin binding and integrins. A 
β1 integrin which is responsible for the binding to ECM molecules of the mesothelial linings, 
additionally collagen and laminin are involved in binding (Ahmed, Riley et al. 2005). Following 
attachment and the upregulation of β1 integrin, the EMT process must be reversed; this 
mesenchymal-epithelial (re-)transition (MET) is required because the properties of EMT 
prevent growth and resocialization of the spheroids (Brabletz 2012). Following this process, a 
matrix metalloprotease (MMP) is activated enabling degradation of the matrix in the 
mesothelial lining. This is a zinc-dependant peptidase which can degrade the ECM, acting 
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specifically to break collagen and fibronectin into smaller fragments. This provides a stronger 
attachment for the newly localised cells. (Ahmed, Riley et al. 2005). At any point throughout 
this process, where the cells require new blood vessels this is initiated by the Vascular 
Endothelial Growth Factor (VEGF). Specifically once cells are in the secondary site, the VEGF 



























Figure 1.4. Ovarian cancer metastasis. (1) Cells undergo EMT in the ovary to loosen individual cells 
from the tumour. (2) Individual malignant cells are released from the ovaries ECM into the 
peritoneum. (3) During transport to new location, malignant cells often reform spheroids to assist 
their survival by creating an optimum environment. (4) EMT changes occur to further increase the 
spheroids survival. (5) The transported spheroids attach to the mesothelial lining of the peritoneum 
through interactions with cadherins and integrins. (6) MET occurs to reverse the initial EMT, 
resulting in the ability of the metastasised cells to grow. (7) Cells migrate further. (8) MMPs act to 
break down the mesothelial lining. (9) The cells enter the peritoneum. 
At most stages of intraperitoneal dissemination, VEGF is present, to allow the cells to grow by 
inducing new blood vessel formation. A process which is vital to ensure the growth of the tumour 
at a new location. 




1.5 Treatment Options for Ovarian Cancer 
1.5.1. Chemotherapy 
The preferred treatment for ovarian cancer has changed over the years from alkylating agents 
to platinum treatments, and more recently to combination therapies containing both 
platinum and taxanes. These all have the potential to kill cancer cells (McGuire and Markman 
2003). In the 1960’s and 1970’s, the treatment of choice was a monotherapy of alkylating 
agents, such as melphalan. Rosenburg et al (1965) subsequently reported that platinum 
compounds can affect cancer cell growth and this led to the introduction of cisplatin (cis-
diamminedichloroplatinum (II)) as an anticancer drug. Cisplatin causes a chemical reaction by 
replacing either one or two chloride ions from the cisplatin with water molecules. This 
ultimately leads to apoptosis via different mechanisms: (1) Once the reaction has taken place, 
it affects the cells pathways responsible for recognising DNA repair mechanisms, which 
interferes with the DNA synthesis for further cell development. (2) The reaction causes 
covalent binding to purine bases, specifically at guanine bases (Reedijk 2003, Kelland 2007). 
These findings resulted in the main treatment option changing from the alkylating agents to 
the platinum treatment. 
 
Cisplatin is highly toxic so the dosage cannot be increased following acquired resistance by 
the cells. To overcome these limitations further research was required to identify a drug that 
was just as successful but with less toxicity (Reedijk 2003). Carboplatin (cis-diammine-[1,1-
cyclobutanedicarboxylato]platinum(II)), a cisplatin analogue, was determined to be suitable 
for replacing cisplatin, with many studies demonstrating similar effectiveness to cisplatin but 
with significantly less toxicity. Carboplatin was introduced as an anti-cancer drug in 1985 
(Adams, Kerby et al. 1989, Christian and Thomas 2001). In contrast to cisplatin, carboplatin 
contains a cyclobutane ring which is more stable than the chlorides present in cisplatin. The 
increased stability and slower reaction time is believed to be the cause of the lower toxicity 
level (Lebwohl and Canetta 1998). 
Although these monotherapy treatments gave improved results against cancer cells, their 
effectiveness was compromised due to increasing resistance of the cells to them. This led to 
the development of combination therapies, using a platinum-based treatment combined with 
one other treatment with the goal of these working synergistically. Taxanes were selected 
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due to their capability of interfering with the functioning of the mitotic spindle through the 
alteration of spindle stability. The taxanes prevent microtubule depolymerisation, resulting in 
the inability to complete mitosis, and thus cause a halt at the M/G2 phase of the cell cycle 
(Agarwal and Kaye 2003). 
The predominant taxane used in drug therapy is paclitaxel. This originates in the tree bark of 
Taxus brevifolia and was discovered as an anticancer treatment in 1971 (Rowinsky 1997, 
McGuire and Markman 2003). This drug is capable of affecting the mitotic spindle by binding 
to 31 amino acids at the N-terminal of β-tubulin, one half of the tubulin heterodimer. 
Additionally paclitaxel affects downstream signalling pathways such as the mitogen activated 
protein kinase (MAPK), which leads to the phosphorylation of the apoptotic protein, BAD, and 
thus stimulates apoptosis (Agarwal and Kaye 2003). When used in combination therapy with 
a platinum based compound, specifically cisplatin, patients responded positively, with an 
increased longevity. This was limited by an increase in toxicity, however this can be somewhat 
countered by treatment with the platinum based drug first, or by replacing the cisplatin with 
carboplatin (Rowinsky 1997, Christian and Thomas 2001) 
Since these drug discoveries, further anticancer drugs are being discovered which improve on 
the efficiency of these previous treatments. Such drugs include docetaxel, a taxane derived 
from needles in the Taxus baccata plant, which in past studies have shown to be as effective 
as paclitaxel but with less toxic effects (McGuire and Markman 2003). 
Although current treatments are giving increased longevity for patients, the mortality rate 
from this disease remains high, so further treatments or drugs need to be determined. 
1.5.2. Surgery  
In addition to the combination therapy of platinum and taxane based chemotherapy, 
debulking, or cytoreductive surgery, is now a common form of treatment for ovarian cancer 
(Ang, Chan et al. 2011). For chemotherapy to be effective, the cytotoxins must be able to 
access the tumour, generally via diffusion. If the tumour is large, the drugs may not be able 
to diffuse to the majority of the tumour due to inefficient blood supply and are therefore 
ineffective. Additionally, larger tumours have an increased chance of acquiring resistance to 
chemotherapeutic drugs (van der Burg, van Lent et al. 1995). Griffiths et al (1975) suggested 
that when a tumours size had been surgically decreased, an increase in the survival rate for 
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patients occurred. Overall, the amount of residual tumour remaining is the best prognostic 
indicator. If the residual tumour is ≤1cm in diameter post-cytoreductive surgery, it is 
considered optimally reduced and potentially increases the survival chance for the patient. In 
contrast, survival rates with tumours larger than 2cm in diameter do not significantly differ to 
those who did not undergo surgery (Ang, Chan et al. 2011). 
Cytoreductive surgery strategies are based on the type of tumour and how advanced the 
growth is. Standard cytoreductive surgery specifically targets the middle abdomen and pelvic 
regions, and often results in the removal of the uterus, cervix, both fallopian tubes and the 
omemtum, the lining of the peritoneal cavity. Patients with more advanced tumours, 
specifically advanced epithelial ovarian cancer, often require more extensive surgery which is 
referred to as radical surgery. This is more invasive and can include the removal of the spleen 
(splenectomy), surgical resection of the pancreas (distal pancreatectomy), resection of the 
liver (hepatic resection), partial removal of the lining of the abdominal cavity (peritonectomy) 
and the removal of the gallbladder (cholecystectomy), (Ang, Chan et al. 2011, Ren, Jiang et al. 
2015). The surgery type is typically dependant on the type of tumour. Young women, with 
low malignant tumours such as stage I epithelial cancer or germ cell tumours may only require 
the removal of the affected ovary, which would allow them to remain fertile, in contrast to 
the more invasive surgeries which can lead to loss of fertility (Berman 2003). 
The capability of the surgeon can limit the effectiveness of surgery, by altering what is  
considered optimal cytoreduction by the surgeon based on their abilities, and also their 
capabilities or preferred techniques may vary from patient to patient (Nguyen, Averette et al. 
1993, Aletti, Dowdy et al. 2006). The aggressiveness of the tumour can also influence the 
overall result despite a tumour being optimally reduced. If the tumour has metastasized, 
surgery may not be a viable treatment option. (Aletti, Dowdy et al. 2006).  
As mentioned above, the mortality rate from ovarian cancer is still very high, despite the fact 
that treatments using surgery are increasing longevity, further research is required to 






The use of radiotherapy as a treatment for ovarian carcinomas dates back to the 1950’s, and 
was commonly used as a subsequent treatment to surgery. Initially there were two treatment 
methods: (1) intraperitoneal radiotherapy, where a radioactive liquid, typically 32P, was put 
directly into the abdomen via a tube, or (2) external whole abdominal radiotherapy (WAR), 
the process of directing an external beam of radiation to the abdomen and pelvic region 
(Cardenes and Randall 2000, Rochet, Sterzing et al. 2010). For advanced ovarian cancer, 
migration to peritoneal surfaces usually occurs and thus WAR became the preferred 
radiotherapy option due to the ability to treat the pelvic region and peritoneal surfaces more 
successfully and with a homogenous distribution (Cardenes and Randall 2000).  
Limitations to the use of WAR included a high acute toxicity level, and a high level of late 
toxicity affecting the bowel resulting in bleeding, perforation and obstruction which is 
typically difficult to treat with surgery. Nearby organs were also a limiting factor. The kidneys, 
liver and small bowel required protection from the radiation which affected the homogeneity 
of this radiation beam and thus resulted in insufficient radiation treatment to these areas. 
Additionally, WAR was only effective on tumours <2cm in diameter. Subsequently, a different 
treatment approach was required and with the improved success rates from the advancing 
chemotherapy regimens, the use of radiotherapy for the treatment of ovarian cancer 
significantly decreased (Rochet, Sterzing et al. 2010). However, research is ongoing to 
determine how to alter the original WAR technique to improve on these limitations. Early 
phase trials have focussed on intensity modulated radiotherapy (IMRT), where the nearby 
tissues and organs at risk are protected whilst still giving a strong and homogenous dose of 
radiation to the peritoneal region. However, further research is required to determine the 
level of toxicity (Rochet, Sterzing et al. 2010). 
The use of radiotherapy for the treatment of ovarian cancer is a controversial topic, and many 
studies suggest different uses for radiation. Specifically the argument that radiotherapy is 
useful when used with chemotherapy on microscopic tumours.  In contrast, some studies 
suggest radiation becomes ineffective due to long rounds of chemotherapy, resulting in 
chemoresistant cells (Cardenes and Randall 2000). In contrast, another study suggested that 
radiotherapy was the best treatment option for chemoresistant cells, and rather than being 
hindered by the resistance, was an effective treatment and gave a better long term prognosis 
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(Machida, Takei et al. 2014). Two studies have suggested the use of radiotherapy as a 
palliative treatment rather than to actually treat the tumour. (Einhorn, Trope et al. 2003, 
Machida, Takei et al. 2014). Additionally, it has been suggested that radiation can be used 
after the completion of treatment to target any residual cancer cells left in the body. This was 
also where IMRT is suggested to be most useful (Rochet, Sterzing et al. 2010). Due to such 
controversy around this treatment option and the differing results from many studies, further 
research is required to understand how best this can be used as a treatment. 
1.6. Natural Substances, Polyphenols and Cancer  
Diet has long been associated with the treatment and/or prevention of various diseases, 
including cancer. Dating back to the 1940’s, natural treatments such as medicinal herbs and 
plant materials have been used as a form of treatment for cancer (Huang, Cai et al. 2009). 
This focus has narrowed over the last 20 years towards polyphenols, secondary metabolites 
present in plants that are used as a defence mechanism against disease from pathogens or 
ultra violet radiation (Manach, Scalbert et al. 2004). Structurally these are composed of at 
least one aromatic ring with at least one hydroxyl group attached and occur in many fruit, 
vegetables and herbs. Polyphenols are natural antioxidants, and therefore may have anti-
tumour properties of varying levels depending on the plant source. These properties include 
the inhibition of angiogenesis (the formation of blood vessels), cell proliferation and 
ultimately the cell cycle (Manach, Scalbert et al. 2004, Han, Shen et al. 2007). During the 
development of cancer, changes occur in the cells which can be the result of oxidative stress 
and the production of free radicals. The antioxidant properties of polyphenols enable the 
scavenging of these free radicals through the donation of a H-atom from its hydroxyl group 
(Duthie, Duthie et al. 2000). An examination of 112 medicinal plants focussing on the effects 
of phenolic compounds has determined that the antioxidant activity was related to total 
phenolic content in the herbs, and confirmed that the herbs with higher levels correlated with 
a decreased cancer incidence. In contrast, dietary fruit and vegetables which contain no 
polyphenols had much lower antioxidant activity, with the exclusion of foods with other 
antioxidants present. The location of  the plant tested appears to be important, as stems and 
leaves differed in their antioxidant levels (Cai, Luo et al. 2004). 
Polyphenols are subdivided as phenolic acids, flavonoids, stilbenes and lignins. These are 
categorised on the basis of the number of phenolic rings they are comprised of, and the 
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overall structure of the compound. This research focuses specifically on stilbenes, which are 
comprised of a 1,2 diphenylethylene nucleus with hydroxyls alongside the aromatic rings and 
occur as either monomers or oligomers (Manach, Scalbert et al. 2004, Han, Shen et al. 2007).  
1.6.1. Resveratrol 
Resveratrol (3,4,5-trihydroxy-trans-stilbene) is a stilbene polyphenol with two aromatic rings 
(Figure 1.5) (Huang, Cai et al. 2009). This compound is present in grapes, red wine and peanuts 
and acts against tumour growth by inducing apoptosis, preventing angiogenesis through the 
alteration of important pathways for growth and the inhibition of cell proliferation. 
Resveratrol has been trialled in the treatment of cardiovascular disease, type II diabetes and 
autoimmune diseases, however current interest has moved to determining its effects on 
cancer. Many tumours including colon, breast, prostate and liver cancers have been reduced 
when treated with resveratrol, however limited research has been done on the effects on 
ovarian cancer (Marques, Markus et al. 2009, Stakleff, Sloan et al. 2012). Resveratrol has been 
shown to induce apoptosis by stabilising the p53 tumour suppressor protein. In ovarian 
cancers where p53 is inactive or apoptotic inhibitors are deactivated, cell death can still occur 
by autophagocytosis, a type II programmed cell death (Opipari, Tan et al. 2004). An alternative 
mechanism may be the down-regulation of glycolysis, an essential process in the metabolism 
of glucose. As autophagocytosis is associated with nutrient deprivation, a decrease in glucose 
leads to cell death via this pathway, supporting the findings of the previous study (Kueck, 
Opipari et al. 2007). 
Most studies have determined differences in the effects resveratrol has in vitro and in vivo 
although continue to use in vitro experiments. These differences may be due to a lack of in 
vivo bioavailability, the amount of unchanged drug that reaches the systemic circulation. It is 
only the bioavailable parts that are accessible to the cancer cells. Using urinary excretion data, 
Walle et al (2004) determined the absorption of resveratrol was at least 70%, however 
bioavailability via oral exposure to resveratrol through ingestion resulted in a value close to 
zero, due to most of the resveratrol being moved through the body and excreted in the urine. 
Small reductions in tumour cells after resveratrol treatment have been observed, specifically 
in the oral cavity  where  resveratrol may have collected in the epithelial cells (Walle, Hsieh et 
al. 2004) 



























The stilbene pterostilbene (trans-3,5-dimethoxy-4-hydroxystilbene) is a dimethylether 
analogue of resveratrol, commonly found in blueberries. Structurally, the two compounds are 
similar, differing only in one functional group, the A-ring; resveratrol contains a 3,5-dihydroxy 
motif compared to pterostilbene which contains a 3,5-dimethyoxy motif (Figure 1.6) (Pan, 
Chang et al. 2007). Pterostilbene has been shown to be more potent than resveratrol, and 
appears capable of inhibiting the cancer growth in both in vitro and in vivo experiments. This 
is likely due to the greater in vivo bioavailability, where 20% is bioavailable, and as such it has 
aroused interest with respect to clinical applications for cancer treatment (Wang, Ding et al. 
2012). 
Similarly to resveratrol, pterostilbene is also believed to affect cellular functions through the 
induction of apoptosis. This occurs through the upregulation of the p53 tumour suppressor 
protein and various other proteins associated with the cell cycle and proliferation, specifically 
cyclins, to prevent cell growth completing a full cell cycle (Pan, Chang et al. 2007, Nutakul, 
Sobers et al. 2011). Further research is required to determine how pterostilbene effects 
tumour growth in ovarian cancer, and whether or not it affects the pathways in similar ways 














1.7. Two Dimensional and Three Dimensional Cell Cultures  
Two dimensional (2D) monolayer cell cultures have been the most commonly used method 
for determining the effects of chemicals on cellular proliferation of cancer cells in vitro. This 
is due to the simple preparation and the long term viability of cells when cultured on a flat 
layer of plastic. However, the optimal functioning of cells in vivo requires signalling; cell-cell 
signalling and signalling with the ECM. This provides the cells with the correct cues for 
proliferation and differentiation. 2D monolayer cultures lack the three dimensional (3D) 
environment experienced by cells in vivo and therefore also lack 3D signalling systems, which 
can result in a different morphology, receptor expression and interactions with the ECM than 
those grown in vivo (Breslin and O’Driscoll 2013). 
To counter these limitations, a three dimensional culture model has been used by some 
researchers. There are many different methods for 3D culturing, including: matrices and 
scaffolds, agitation based approaches such as spinning or rotation, the hanging drop method 
and the forced floating method, which is the most commonly used method and the one that 
is used in this research. The forced floating method forces the cells away from the culture 
flask or well plates surface to bring the cells together to form spheroids (Breslin and O’Driscoll 
2013). This enables the cluster of cells to have similar morphology to spheroids in vivo, as the 
cultured spheroids contains cells which are exposed to the external surface and cells that are 
not. These different environments lead to different cell behaviours, for example, some cells 
will proliferate while others will be non-proliferating, as observed in vivo. (Yamada and 
Cukierman 2007). Additionally, due to the structure of the spheroid, the cells are more likely 
to be able to maintain cell-cell and cell-ECM interactions and signalling patterns, and thus are 
more likely to behave similarly to in vivo spheroids (Grun, Benjamin et al. 2009). 
For drug discovery and development, 3D cultures have been shown to be better for examining 
the effects of drugs. As the effects of drugs on growth and  cellular pathways are thought to 
reflect spheroids in vivo, this technique is beneficial  for researching and testing 




1.8. Aims and Hypotheses 
1.8.1. Aims 
Given that there have been many studies done on the effects of resveratrol on cancer cells, 
but few which have focussed on the effects in ovarian cancer, the aim of this research is to 
investigate the effects of resveratrol and its anologue, pterostilbene on two ovarian cancer 
cell lines, OVCAR-5 and SKOV-3. This study aims to determine the effect of these drugs on: 
cellular growth and metabolism, the vascular endothelial growth factor and the protein levels 
of EGFR, pEGFR, HER2, pHER2, AKT, pAKT, cyclin D2 and PCNA in order to investigate how 
various protein pathways are affected by these drugs. The effects of the drugs will be tested 
at various concentrations. 
1.8.2. Hypotheses  
I hypothesise that resveratrol and pterostilbene will exhibit anti-cancerous effects on both 
the OVCAR-5 and SKOV-3 cell lines. Based on previous findings stating pterostilbene is more 
potent, I hypothesise that pterostilbene will be more anti-cancerous than resveratrol, causing 
significant changes to proliferation and metabolism. Lastly I hypothesise that both these drugs 
will interfere with pathways required for tumour growth, such as the production of VEGF, and 
the proteins: EGFR, pEGFR, HER2, pHER2, AKT, pAKT, cyclin D2 and PCNA. 
1.8.3. Model Cell Lines 
The two ovarian cancer cell lines that were used in this research were SKOV-3 and OVCAR-5. 
SKOV-3 is the conventional serous carcinoma cell line (Singer, Oldt et al. 2003). SKOV-3 has 4 
gene mutations, these occur in: the cyclin dependant kinase inhibitor 2A (CDKN2A) which is 
associated with p16, the mismatch repair gene MLH1, PIK3CA and in the tumour suppressor 
gene TP53. Both BRCA1 and BRCA2 remain normal in these cells. SKOV-3 cells are resistant to 
tumour necrosis factor and to various cytotoxic drugs (American Type Culture Collection). 
OVCAR-5 cells have a substitution mutation in the KRAS gene and a normal BRAF gene. Both 
BRCA genes are normal. Similar to SKOV-3, both the TP53 tumour suppressor gene and 
CDKN2A genes are also mutated (The Roche Cancer Genome Database 2.0). Both cell lines 




Chapter 2: Materials and Methods 
2.1. Materials 
2.1.1. General Materials 
2.1.1.1. 10X PBS (500mL) 
For the stock PBS buffer 7.1g Na2HPO4 was dissolved in 500mL of MilliQ H2O, and NaH2PO4 
was added until the pH was 7.1. NaCl and KCl were then added to adjust the pH to 6.7-6.8. 
The 10X PBS was further diluted to 1X using MilliQ H2O when required. 
 
2.1.1.2. 10X Trypsin-Ethylenediamine Tetraaccetic Acid 
(200mL) (Trypsin-EDTA) 
Trypsin EDTA solution was made up using the following: 5g Trypsin powder and 1.5g EDTA 
were mixed in 200mL 1X PBS and adjusted to pH 8 using NaOH pellets.  
2.1.1.3. Dulbecco’s Modified Eagle Medium: Nutrient 
Mixture F12 (DMEM-F12) 
For the Dulbecco’s modified Eagle media 1L of 10X base media was made up directly following 
the instructions on the packet under sterile conditions. 1 packet of alpha medium and 2.438g 
NaHCO3 were dissolved in MilliQ H20 and the pH was adjusted to 7.1-7.3. The base media was 
then sterilised by filtration. 
The working media was made up under sterile conditions using 20mL FBS (5%), 4mL 1X 
PenStrep, 4mL 1X Glutamax and 400µL fungizone, all of which were added to 400mL of base 
media in a sterile bottle. This media from here on is referred to as working media. 
2.1.1.4. Poly-hydroxyethylmethacrylate (Poly-HEMA) 
For the Poly-HEMA solution, for a final concentration of 12mg/mL, 1.2g Poly-HEMA powder 
was dissolved in 100mL of 95% ethanol and heated to 70°C to completely dissolve the 
PolyHEMA. This was stored under sterile conditions until required for plating. After storage, 





2.1.1.5. Crystal Violet Solutions 
For the Tris(4-(dimethylamino)phenyl)methylium chloride (crystal violet dye) 0.2% crystal 
violet powder was mixed with 100mL 2% ethanol. 
For the Sodium dodecyl sulphate (SDS), this was diluted to 2% using MilliQ H2O 
2.1.2. Anti-Cancerous Drugs 
Resveratrol was dissolved in 100% PBS pH 7.4. 
Pterostilbene was dissolved in 100% DMSO. 
 
2.1.3. ELISA: Buffers and Solutions 
 
The washing buffer contained 0.05% Tween20 in 1x PBS pH 7.4. 
The reagent diluent contained 2% BSA in 1X PBS pH 7.4. 
 
2.1.4. Western Blot: Buffers and Solutions 
 
2.1.4.1. 2M Tris-HCl (pH 7.5) 
 
2M Tris-HCl was made up using the following: 24.2g Tris base, concentrated HCL to make pH 
7.5, then MilliQ H2O to make up to 100mL. 
 
2.1.4.2. 1M Tris-HCl (pH 6.8) 
 
1M Tris-HCl was made up using the following; 12.1g Tris base, concentrated HCl to make the 
pH 6.8, then MilliQ H2O to make up to 100mL. 
 
2.1.4.3. Running Buffer 
 
The electrophoresis buffer contained 50ml Bolt™ 1X MES SDS running buffer and was made 





2.1.4.4. Tris Buffer Saline (TBS) 
 
TBS was made up containing; 10mL 2M Tris-HCl (pH 7.5), 8.18g NaCl and MilliQ H2O to make 
it up to 1L.  
TBS-T was made up by adding 1mL Tween-20 to TBS. 
 
2.1.4.5. 5x Sample Buffer 
 
10mL Sample Buffer was made up containing; 0.6mL 1M Tris-HCl (pH 6.8), 5mL 50% glycerol, 
2mL 10% SDS, 2mL 1% bromophenol and 0.8mL MilliQ H2O 
 
2.1.4.6. Transfer Buffer 
 
Transfer buffer was made up containing; 1.93g Tris, 9g glycine in 1L MilliQ H2O 
 
2.1.4.7. Blocking Solutions 
 
Blocking solutions were made up using either 5% (w/v) low-fat skim milk or 1% (w/v) BSA in 
TBS-T 
 
2.1.4.8. Antibody Solutions 
 
Antibody solutions were made up using solutions were made up using either 5% (w/v) low-




2.2.1. Two Dimensional Cell Culture 
The two cell lines, OVCAR-5 and SKOV-3, were obtained from Dr Kenny Chitcholtan 
(Department of Obstetrics and Gynaecology, University of Otago, Christchurch), and 
maintained in a 50mL culture flask with DMEM-F12 working media, at 37°C in a humidified 
5% CO2 incubator. The media was replaced every 2 days, until the cells reached near 
confluence, as determined using a light microscope. Once about 90% confluent, the cells were 
subcultured. In a cell culture laminar flow cabinet, the used media was discarded and the 
culture flask was rinsed once with sterile 1X PBS before incubating with sterile 1X Trypsin-
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EDTA for 20-30 minutes to detach the cells from the culture flask surface. Cells were then 
transferred to a 50mL tube and centrifuged at 1500rpm for 5 minutes. The supernatant was 
discarded. The cells were resuspended in 7mL of fresh working media and a sample of this 
suspension was transferred to a new culture flask and mixed with fresh working media to 
make up to 6ml total volume. 
2.2.2. Three Dimensional Cell Culture 
For the generation of multicellular spheroids in a 3D culture, 12-well plates were pre-coated 
with 12mg/ml Poly-HEMA and incubated at 37°C on an orbital shaker set at 50rpm for 24 
hours, to prevent cell adhesion to the culture wells. Before use, the 12-well plates were 
washed once with 1X PBS. Cells were subcultured from 2D monolayer following the above 
methods. Once the cells were resuspended in fresh working media, 100µL of resuspended 
cells and 100µL 1X PBS were transferred into an eppendorf tube and cells were counted using 
a haemocytometer to determine the approximate cell number in the cell suspension. Cells 
were then plated at approximately 200,000 cells per well on a 12-well plate. Media was 
changed every 2 days for 6 days by tilting the plate for about 5 minutes to allow cells to 
accumulate at the bottom of the well before aspirating off the media. The media was replaced 
with 1mL fresh working media.  
2.2.3. Drug Treatment 
On the sixth day of 3D culturing, the media was removed by tilting the 12-well plate for 
approximately 5 minutes to allow the cells to accumulate in the bottom of the well. The media 
was then aspirated off and 1ml of fresh working media containing the specific drug 
concentration of resveratrol or pterostilbene treatment (10µM, 30µM and 50µM) was added. 
For pterostilbene experiments, control cells were incubated with the highest concentration 
of solvent (DMSO) used for dissolving pterostilbene in. For resveratrol, the control consisted 







2.2.4. Cell Morphology 
Following 6 days of drug treatment, images were collected using a Leica DFC290 camera 
attached to an inverted light microscope with a 20X/NA=0.4 objective lens for spheroid 
morphology. Spheroid size was measured using a micrometre slide. 
2.2.5. Alamar Blue Assay  
Alamar Blue (resazurin) is a metabolism-sensitive dye used to determine the viability, and the 
migratory and invasive characteristics of cells. When the dye is added to a sample it has a blue 
colour and is non-fluorescent, but when reduced by components of metabolism, for example 
mitochondrial enzymes or cytochromes, it becomes pink and fluorescent (Vega-Avila and 
Pugsley 2011). After 11 days of 3D cell culturing, the 12-well plate was tilted to collect the 
cellular spheroids in the bottom of the well and 0.5mL of culture media was aspirated off. 
50µL Alamar Blue dye was added to each of the wells and incubated at 37°C for 4 hours. 
Following incubation, 200µL from each sample was loaded onto a 96-well plate. The optical 
density was the difference between values determined using 570nm (OD570) and 600nm 
(OD600) on a microplate reader. Measurements for each sample were made in triplicate. 
2.2.6. Crystal Violet Assay  
Crystal violet assays are used to assess cell viability and quantify cell number through staining 
and determination of optical density. The violet dye stains the cellular DNA, therefore the 
more intense the staining, the more cells are present and viable (Vega-Avila and Pugsley 
2011). Following the Alamar Blue assay, the remaining Alamar blue dye was aspirated off and 
the 12 wells were rinsed with 1X PBS. Cells were then collected in 4mL round bottom 
eppendorf tubes (1 tube for each well) and centrifuged for 5 minutes at 2500rpm. The 
supernatant was discarded and the pellet was mixed with 1X PBS and centrifuged at 2500rpm. 
The supernatant was again discarded and 300µL 1X PBS and 700µL 10X trypsin-EDTA was 
added to the eppendorf tube to break up the spheroids. After 30 minutes of incubation at 
37ׄ°C with mixing every 10 minutes, the eppendorf tubes were centrifuged at 2500rpm for 5 
minutes, and the supernatant was again discarded. 200µL of crystal violet dye was added to 
each tube and left at room temperature for 30 minutes. The cells were then washed with 
MilliQ H20 and centrifuged, discarding the supernatant each time. This washing was repeated 
until all excess dye was removed and the supernatant was clear. The cells were then lysed 
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with 2% (w/v) SDS and left in room temperature for 10 minutes. 200µL from each sample was 
then added to a 96-well plate. The optical density was determined at 560nm (OD560) on a 
microplate reader. Measurements for each sample were made in triplicate. 
2.2.7. Vascular Endothelial Growth Factor ELISA 
The secretion of VEGF produced by the OVCAR-5 and SKOV-3 spheroids was measured using 
the DuoSet Human VEGF ELISA kit (R&D systems, New Zealand). Following 6 days of drug 
treatment the cultured spheroids in growth media were centrifuged at 2000rpm for 5 minutes 
and the supernatant was aspirated off and frozen at -80oC. To start the ELISA, a 96 well plate 
was coated with the capture antibody diluted in 1X PBS pH 7.4 and incubated at room 
temperature overnight. The next day the wells were washed four times using the wash buffer 
and then blocked using reagent diluent and incubated for 1 hour. The wells were again 
washed with the wash buffer 4 times before adding the cell media samples and VEGF 
standards (2ng/mL, 1ng/mL, 0.5nm/mL, 0.25ng/mL, 0.125ng/mL, 0.06ng/mL and 0.03ng/mL 
of VEGF standard diluted in reagent diluent) to the designated wells and incubated for 2 
hours. Wells were washed 4 more times and the detection antibody diluted in reagent diluent 
was added to the wells and incubated at room temperature for a further 2 hours before being 
washed with washing buffer 4 more times. Following washing, streptavidin-HRP diluted in 
reagent diluent was added to each well and incubated in the dark for 20 minutes. The wells 
were then washed with washing buffer 4 times before adding TMB-substrate and incubating 
for 20 minutes at room temperature. After 5 minutes 2NH2SO4 was added to stop the reaction 
and the optical density was then read at 450nm (OD450) using a microplate reader. The 
samples were then plotted against a graph of the standards to determine the concentration 
of VEGF in each sample. Each treatment was tested in triplicate. 
2.2.8. BCA Protein Assay 
A protein assay was used to determine the concentration of protein present in the cell pellets 
to normalise the amount of protein that was run for the western blot. A BCA™ Protein Assay 
kit (Pierce, Thermo Fisher Scientific, Rockford, IL, USA) was used to determine protein levels 
in each sample by comparing samples to a standard curve from known concentrations of BSA. 
Cells were centrifuged at 2000rpm for 5 minutes and the media was aspirated off. Cell pellets 
were lysed by adding 200µL of 0.1% SDS to each cell sample, and 12.5µL of each sample and 
41 
 
standards were loaded into a 96 well plate. 200µL of BSA working reagent was added to each 
well. Cells were shaken for 30 seconds then incubated at 37°C for 30 minutes. Absorbance 
was read at 562nm using a microplate reader, and protein concentration determined to give 
10µg protein per sample for loading in the gel. 
2.2.9. Western Blotting 
Following the BCA protein assay, each cell lysate was prepared for gel loading by mixing them 
with 20µL 5x sample buffer. Samples were then vortexed and heated at 100°C for 10 minutes 
then cooled on ice for 10 minutes and centrifuged at 10,000rpm for 10 minutes. Samples were 
loaded into Bolt™ 4-12% Bis-Tris Plus gels at the volume required to give 10µg protein. 
MagicMark™ Western Standard (Invitrogen, New Zealand) and Precision Plus Protein™ Duel 
Colour Standards (BIO-RAD, New Zealand) were used as gel markers. Gels were run in Bolt™ 
MES SDS Running Buffer (1X) for approximately 120 minutes at 120 Volts. Polyvinyl difluoride 
(PVDF) membranes (BIO-RAD, Hercules, USA) were soaked in methanol for 5 minutes and 
then in cold transfer buffer for 15 minutes and then the separated proteins were transferred 
to the membranes using a Trans-Blot® SD cell (BIO-RAD, New Zealand) for 60 minutes at 15 
Volts. Following transfer, gels membranes were blocked with blocking solution specific to 
each protein for 60 minutes (Table 2.1). Blocking buffer was then discarded and membranes 
soaked in the diluted primary antibody solution at 4°C overnight (Table 2.1). Primary antibody 
solution was then discarded and membranes washed four times in fresh TBS-T for 10 minutes 
on an orbital shaker at 20rpm. Membranes were then incubated in the appropriate secondary 
antibody solution for 90 minutes at room temperature on an orbital shaker at 10rpm (table 
2.1). Membranes were then washed as before with fresh TBS-T. The developer (Clarity™ 
Western ECL Substrate, BIO-RAD, USA) was used to image protein bands and densitometry 































Mouse 1/500 1% (w/v) 
BSA 
1/10000 



























Rabbit 1/500 1% (w/v) 
BSA 
1/10000 




























 sc-25778, c2415 







Mouse 1/500 5% Skim 
milk 
1/1000 
Table 2.1. Working concentrations of antibodies used for Western Blots. Both secondary 
antibodies obtained from ThermoFisher Scientific and were raised in goat. 
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2.2.10. Statistical Analysis 
Statistical analysis was performed using GraphPad Prism® software (La Jolla, CA, USA). 
Experimental results were assessed for significance using a one way ANOVA followed by a 




























Chapter 3: Effects of Polyphenols on Cellular 
Metabolism and Growth of Ovarian Cancer Cells  
3.1. Introduction 
3.1.1. The Cell Cycle and Ovarian Cancer 
The cell cycle and its importance was introduced in section 1.3. Different regulators are 
required at each of the cell cycle checkpoints. For G1/S phase regulation, cyclin D1, CDK4 and 
p16 have significant roles (Figure 1.3). The gene which encodes the 36kDa cyclin D1 protein, 
(CCND1), is usually regulated by mitogens, which induce the cell cycle. However, during 
tumourigenesis, this gene can be altered, resulting in gene deregulation and an 
overexpression of cyclin D1. When cyclin D1 is present in the nucleus, the cell cycle will 
progress beyond the G1 checkpoint. In ovarian cancer, when there is overexpression of D1 in 
the nucleus, it will bind with CDK4 or CDK6, which enables the cell cycle to continue (Dhar, 
Branigan et al. 1999). The overexpression of CDK4 has been observed in up to 15% of large 
ovarian tumours (D’Andrilli, Kumar et al. 2004). A tumour suppressor protein, p16, binds to 
the CDKs in normal cells to prevent association with the cyclins and thus these function in 
tumour suppression. This role is important, as it prevents phosphorylation and activation of 
the retinoblastoma protein, a tumour suppressor protein, and thus is responsible for stopping 
the cell cycle if there is damage. This process can become interrupted allowing the formation 
of ovarian carcinomas by preventing the cell regulation system functioning  (Fang, Jin et al. 
1998, Bali, O’Brien et al. 2004). Fang, Jin et al. (1998) found a deletion in p16 occurred in 50% 
of the ovarian cancer cell lines that they tested. 
A second pathway for regulating the G1/S transition checkpoint involves cyclin E, CDK2 and 
inhibitors of Cip/Kip. Similar to cyclin D, cyclin E is overexpressed in ovarian tumours. The 
overexpression has been found to occur in up to 45% of ovarian cancers and the level of 
overexpression appears to be associated with the malignancy of the tumour; benign tumours 
have little overexpression, in contrast to malignant tumours have greater overexpression. 
Thus, the overexpression of cyclin E affects both development and malignancy. This 
overexpression is matched by CDK2, which is associated with cyclin E, and similarly there is 
more overexpression of this protein in malignant tumours. Two Cip/Kip CDK inhibitors, p27 
and p21 also affect this pathway. In normal cells, p21 is present in the cell nucleus, which 
45 
 
enables it to bind the CDKs and prevent cyclin binding, which subsequently prevents the 
transition to the S phase of the cell cycle. In cancer cells p21 can become overexpressed, 
resulting in its presence in the cytoplasm, where it becomes inactive. In contrast, p27 is down 
regulated in ovarian cancer cells. Similarly to p16, due to the decreased amount of p27, the 
cyclin-CDK complex can form even under conditions where there is damage, further enabling 
cellular proliferation. (Kim, Shim et al. 2003). 
3.1.2. Cellular Metabolism and Cancer 
Metabolic adjustment is an important process for continued proliferation in cancer cells. With 
each cell division, the production of proteins, nucleic acids and lipids is required for both 
daughter cells, thus the metabolic process must change to facilitate increased production of 
these (DeBerardinis, Sayed et al. 2008). An increase in the activity of the glycolytic pathway 
leads to the increased production of ATP and other metabolites that are required for growth. 
Although there is an increase in glucose consumption in proliferating cancer cells, most of this 
is converted to lactate and little is used for cellular respiration; this has been referred to as 
the Warburg effect (Munoz-Pinedo, El Mjiyad et al. 2012). This is advantageous for cancer 
cells, because it allows them to grow in hypoxic conditions, where they wouldn’t be able to 
survive if they relied simply on aerobic respiration. Additionally, by producing lactate as an 
end product, it acts to provide a favourable condition for further cell growth by acting against 
immune responses that could potentially target the abnormal cells (Kroemer and Pouyssegur 
2008). Proliferating cells use glucose uptake to activate the pentose phosphate pathway, 
leading to the production of nucleic acids. Due to the importance of cellular metabolism in 
proliferation and subsequently cell migration, metabolic processes are a desirable target for 
drug treatments as a slowed down metabolism, or one which cannot adjust could have 
significant effects in treatment. 
3.1.3. Aims of Chapter 3 
The aim of this chapter is to investigate the effects of resveratrol and pterostilbene on cell 





3D Cell culture – See chapter 2 for details. 
Alamar Blue Assay – See chapter 2 for details. 
Crystal Violet Assay – See chapter 2 for details. 
3.3. Results 
3.3.1. Effect of Resveratrol on Spheroid Morphology 
Resveratrol treatment had no obvious effect on spheroid morphology at 10µM, relative to 
the control, while a decrease in spheroid number was observed after 30µM and 50 µM 
treatments (Figure 3.1). The average size of the OVCAR-5 control spheroids was 49.14µm. No 
significant decrease in spheroid size occurred at any resveratrol concentration tested (Figure 
3.5a).  
Resveratrol treatment on SKOV-3 cells had no obvious effect on spheroid morphology at any 
of the concentrations tested, and spheroids did not start to break apart. Spheroids appeared 
to be highly layered and thus measuring individual spheroid size was not viable due to lack of 
clear outlines or separate spheroid clusters (Figure 3.2).  
3.3.2. Effect of Pterostilbene on Spheroid Morphology 
Treatment of OVCAR-5 spheroids with pterostilbene had no obvious effect on morphology at 
10µM relative to the control, however there was a decrease in spheroid number at 
concentrations of 30µM and 50µM (figure 3.5). Exposure to 50µM pterostilbene resulted in a 
significant decrease in average spheroid size relative to the other treatment concentrations 
tested (P≤0.0001, ANOVA, n=29) (Figure 3.5b).  
The effect of pterostilbene treatment to SKOV-3 spheroids was a decreasing trend in overall 
spheroid size relative to the control for each concentration tested. Following 50µM 
pterostilbene, the spheroids were broken up into smaller clusters in addition to the decrease 
in overall size. The SKOV-3 cell line has a high level of cell layering and thus actual spheroid 









Figure 3.1. OVCAR-5 spheroids after treatment with resveratrol. The images show the effects 
of (A) no resveratrol (control); (B) 10µM resveratrol; (C) 30µM resveratrol; and (D) 50µM 
resveratrol. Differences in the number of spheroids present occurred with the 30µM treatment 













Figure 3.2. SKOV-3 spheroids after treatment with resveratrol. The images show the effects 
of (A) no resveratrol (control); (B) 10µM resveratrol; (C) 30µM resveratrol; and (D) 50µM 













Figure 3.3. OVCAR-5 spheroids after treatment with pterostilbene. The images show the 
effects of (A) no pterostilbene (control); (B) 10µM pterostilbene; (C) 30µM pterostilbene; 
and (D) 50µM pterostilbene. A difference in the number of cell clusters occurred following 










Figure 3.4. SKOV-3 spheroids after treatment with pterostilbene. The images show the effects 
of (A) no pterostilbene (control); (B) 10µM pterostilbene; (C) 30µM pterostilbene; and (D) 
50µM pterostilbene. Spheroid size decreased at the higher concentrations and spheroids 














Figure 3.5. OVCAR-5 spheroid size following treatment with (A) resveratrol and (B) pterostilbene at 0µM 
(control), 10µM, 30µM and 50µM. Measurements were taken from images obtained using light 






3.3.3. Effect of Resveratrol and Pterostilbene on Metabolic Activity 
of OVCAR-5 and SKOV-3  
The metabolic activity of OVCAR-5 spheroids was significantly reduced in the presence of 
50µM resveratrol (P≤0.05, ANOVA, n=9) (Figure 3.9). The metabolic activity was also 
significantly lower in the 50µM treatment relative to the 30µM treatment (P≤0.05, ANOVA, 
n=9). The lower resveratrol concentrations (10µM and 30µM) did not show any significant 
difference relative to the control (Figure 3.9a). There was no significant change in OVCAR-5 
metabolic activity in response to pterostilbene at any of the tested concentrations relative to 
the control (P>0.05, ANOVA, n=9) (Figure 3.9b). 
The metabolic activity of SKOV-3 spheroids was not significantly reduced at any of the 
concentrations of resveratrol tested (Figure 3.10a) (P>0.05, ANOVA, n=9). In contrast, there 
was a statistically significant reduction in metabolism in the presence of 30µM (P≤0.001, 
ANOVA, n=9) and 50µM (P≤0.0001, ANOVA, n=9) pterostilbene. The 50µM pterostilbene 
treatment also gave a statistically significant decrease in metabolic activity relative to the 
10µM and 30µM treatments (Figure 3.10b). 
DMSO at the highest concentration tested had no effect on metabolic activity relative to the 
DMEM-F12 control (Table  3.1).  
3.3.4. Effect of Resveratrol and Pterostilbene on Cellular 
Quantification of OVCAR-5 and SKOV-3  
The number of OVCAR-5 cells was significantly reduced in the presence of 50µM resveratrol 
(P≤0.05, ANOVA, n=9) (Figure 3.11a). At lower concentrations there was no significant effect 
on cell number. Pterostilbene, significantly decreased the number of OVCAR-5 cells at 
concentrations of 30µM (P≤0.01, ANOVA, n=9) and 50µM (P≤0.001, ANOVA, n=9). 
Additionally, the 50µM treatment significantly decreased cell number relative to the 10µM 
treatment (Figure 3.11b).  
Resveratrol had no significant effect on the number of SKOV-3 cells at any of the 
concentrations tested (P>0.05, ANOVA, n=9). In contrast, pterostilbene significantly reduced 
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SKOV-3 cell number at each of the concentrations tested: 10µM (P≤0.001, ANOVA, n=9), 
30µM (P≤0.0001, ANOVA, n=9) and 50µM (P≤0.001, ANOVA, n=9) (Figure 3.12b). 
Again DMSO controls similar to those used in the pterostilbene samples were found to have 













Figure 3.6. Cell metabolism as determined by an Alamar Blue assay of OVCAR-5 cells treated with (A) 
resveratrol and (B) pterostilbene at 0µM (control), 10µM, 30µM and 50µM. Data was normalised and the 
control had a mean absorbance value of 0.435nm and 0.212nm for the resveratrol and pterostilbene 
samples respectively. Data was collected from three individual experiments and carried out in triplicate ± 
SEM. * denotes statistical significance (P≤0.05, ANOVA, n=9) relative to the control. 
Figure 3.7. Cell metabolism as determined by an Alamar Blue assay of SKOV3 cells treated with (A) 
resveratrol and (B) pterostilbene at different concentrations (0µM (control), 10µM, 30µM and 50µM). 
Data was normalised and the control has a mean absorbance value of 0.321nm and 0.372nm for 
resveratrol and pterostilbene samples respectively. Data is collected from three individual experiments 
carried out in triplicate ± SEM. * denotes statistical significance (P≤0.05 ANOVA,) relative to the control. 
*** denotes statistical significance (P≤0.001, ANOVA,) relative to the control. **** denotes statistical 





Figure 3.8. Number of OVCAR-5 cells determined by the Crystal Violet assay after treatment with (A) 
resveratrol and (B) pterostilbene at different concentrations (0µM (control), 10µM, 30µM and 50µM). Data 
was normalised and the control has a mean absorbance value of 0.757nm and 1.162nm for resveratrol and 
pterostilbene samples respectively. Data is collected from three individual experiments carried out in 
triplicate ± SEM. * denotes statistical significance (P≤0.05, ANOVA), ** denotes statistical significance (P≤0.01, 
ANOVA) and *** denotes statistical significance (P≤0.001, ANOVA) relative to the control.  
Figure 3.9. Number of SKOV-3 cells determined by Crystal Violet assay after treatment with (A) resveratrol and 
(B) pterostilbene at different concentrations (0µM (control), 10µM, 30µM and 50µM). Data was normalised 
and the control has a mean absorbance value of 0.769nm and 1.756nm for resveratrol and pterostilbene 
samples respectively. Data is collected from three individual experiments carried out in triplicate ± SEM. * 
denotes statistical significance (P≤0.05, ANOVA), ** denotes statistical significance (P ≤ 0.01, ANOVA), *** 
denotes statistical significance (ANOVA, P ≤ 0.001) and **** denotes statistical significance (P≤0.0001, 












OVCAR-5 0.354 0.476 no 













OVCAR-5 1.016 0.876 no 










Table 3.1. Comparison between cell metabolism in the control media and control media 
with added DMSO. There was no significant difference in metabolism and thus DMSO did 
not affect cell metabolism. 
Table 3.2.  Comparison between cell number in control media sample and control media 
with added DMSO. There was no significant different in cell number and thus DMSO did 





The preventative and/or curative effects against cancer cells of natural products present in 
the diet is an area that is of current interest given the possible resistance of these cells to 
chemotherapy and the toxicity of the chemotherapeutic drugs. Two such compounds, the 
stilbenes resveratrol and pterostilbene were the focus of the current research. Previous 
research on resveratrol has focussed on colon, breast and prostate cancer and has shown that 
the compound reduced cell proliferation and growth (Aziz, Kumar et al. 2003). Research on 
pterostilbene has shown that the compound reduced cell proliferation and growth in a dose-
dependent manner in bladder, pancreas, colon, breast, prostate and stomach cancers. 
However research on the effects of both these stilbenes on ovarian cancer cells has been 
limited (McCormack and McFadden 2012, Stakleff, Sloan et al. 2012). This chapter focussed 
on the effects of these two stilbenes on metabolism and cell number of the OVCAR-5 and 
SKOV-3 ovarian cancer cell lines. 
The effect of resveratrol on ovarian cancer was cell line dependant; OVCAR-5 had a 
significantly decreased cell metabolism and cell number; in contrast resveratrol had no 
significant effect on the SKOV-3 cells. Furthermore, these decreases in OVCAR-5 were dose 
dependant; only 50µM resveratrol caused a significant decrease in cell metabolism and 
number. This is in line with a previous study which tested the effects of resveratrol on 6 
different cell lines from different cancers (colon, oesophageal, leukaemia and breast cancer) 
at various concentrations of resveratrol (0µM, 30µM, 50µM, 100µM, 200µM and 300µM). All 
cell lines showed a significant reduction in growth after exposure to 100µM resveratrol, and 
three (oesophageal adenocarcinoma Seg-1, leukaemia HL-60 and breast MCF-7) were more 
sensitive with a significant reduction after exposure to 50µM resveratrol (Joe, Liu et al. 2002). 
There are similarities between various breast and ovarian cancers, specifically in the germline 
mutations BRCA1 and BRCA2, and genetic mutations in PTEN, CDH1, PALB2 and TP53 
(National Cancer Institute). Due to the similarities in genetic mutations between breast and 
ovarian cancer, the similarity in growth inhibition of the breast cancer cell line tested by Joe, 
Liu et al. (2002)  and the OVCAR-5 result from the present study would encourage further 
concentrations of resveratrol to be tested on ovarian cancer cell lines to determine if a similar 
pattern would occur.  
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There are limited studies which have made a comparative examination of the effect of 
resveratrol on different ovarian cancer cell lines. Lee, Choi et al. (2009) examined three 
different ovarian cancer cell lines: PA-1, TOV-112D and SKOV-3, in a monolayer culture with 
increasing levels of resveratrol (0µM, 12.5µM, 25µM, 50µM, 100µM and 200µM), to which 
the cells were exposed for different lengths of time. Similar to the present study, SKOV-3 
growth was not significantly reduced when the resveratrol concentration was less than 50µM. 
The higher non-physiological levels of resveratrol (≥50µM) produced significant decreases, 
demonstrating dose dependency, an effect not tested in the present study as concentrations 
tested did not exceed 50µM. The three cell lines tested by Lee, Choi et al. (2009) differed in 
their responses to resveratrol, as did the SKOV-3 and OVCAR-5 in the present study. This 
further suggests that, in addition to different cancer types responding differently to the 
compound, different cell lines of the same cancer can have a different responses. Thus the 
different mutations in these cells lines may lead to differing sensitivities to resveratrol. 
 The OVCAR-5 cell line contains a KRAS:G12V mutation, while SKOV-3 has the wild type gene. 
This mutation leads to a missense substitution in the KRAS gene, which can result in the 
activation of the MAPK/ERK pathway and subsequently effects cell cycle progression and cell 
motility (The Roche Cancer Genome Database 2.0). SKOV-3 contains a missense mutation in 
H1047R, leading to a mutated PIK3CA gene, while OVCAR-5 contains the wild type. This could 
potentially affect the PI(3)K signalling pathway and ultimately increase migration and 
tumourigenesis. Treatment with resveratrol at high concentrations could affect these 
proteins differently, to cause a change to the level of proliferation in these cell lines. Further 
research would be required to determine this. 
There are few studies that have investigated the anti-cancerous effect of resveratrol on 
ovarian cancer 3D spheroids.  A recent study focussed on the effects of resveratrol and several 
of its derivatives on the SKOV-3 cell line and demonstrated significant reduction in cell growth 
at concentrations of 10 and 50µM resveratrol (Hogg, Chitcholtan et al. 2015). This study used 
similar techniques to those in the present study, so the difference in the reported results and 
in the present study are difficult to explain. Different laboratories and different batches of 
chemicals used may be a factor in why these two studies gave different results. Cells for the 
current study were donated from the other laboratory, thus the cells may have acquired 
resistance to resveratrol over time prior to the current study being carried out.  
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The decrease in cellular metabolism following resveratrol treatment was cell line- and dose-
dependent, as resveratrol caused a significant decrease only at 50µM in the OVCAR-5 cell line. 
A previous study tested the effects of resveratrol on glucose metabolism in several cell lines, 
including two types of OVCARs and SKOV-3 (Kueck, Opipari et al. 2007). The study revealed 
that resveratrol acts as a starvation agent, resulting in a decrease in glucose uptake and 
subsequently glucose metabolism. A greater decrease in glucose uptake was observed in the 
OVCA432 and OVCA429 cell lines compared to SKOV-3 with 50µM resveratrol (Kueck, Opipari 
et al. 2007). The DMEM/F12 media used in the current study is high in glucose, which thus 
suggests that a similar decrease in glucose uptake may be responsible for the results in the 
current study. This is consistent with the OVCAR-5 spheroids being more sensitive to 
resveratrol than the SKOV-3 cells. 
As hypothesised, pterostilbene had a greater effect than resveratrol; pterostilbene caused 
significant decreases in cell number at lower concentrations in both OVCAR-5 and SKOV-3 
cells and a decrease in cell metabolism in SKOV-3 cells. Cell number was significantly 
decreased in SKOV-3 spheroids following 10µM, 30µM and 50µM treatment, in contrast to 
OVCAR-5 which was only significantly decreased at 30µM and 50µM. The level of significance 
for the decrease in OVCAR-5 cell number following 50µM treatment was in the same range 
as the significance for the 10µM treatment on SKOV-3, further demonstrating the differences 
this compound has on the two different cell lines. Pterostilbene produced a dose- and cell 
line- dependent effect on metabolism. SKOV-3 spheroids resulted in a significant reduction 
following treatment with 30µM and 50µM pterostilbene. There was no significant decrease 
in metabolism at any tested concentration of OVCAR-5 or following the 10µM pterostilbene 
treatment of SKOV-3 cells, even though there was a decrease in cell number. This result is 
difficult to explain as it would be expected that a decreasing number of viable cells would 
occur when there was a decrease in cell metabolism. This could be due to the size of the 
spheroids and the methodology for testing metabolism. Spheroids are quite large, especially 
the OVCAR-5 spheroids and because the cells were not trypsinized before the addition of the 
Alamar Blue dye with incubation, the dye may only be interacting with the cells on the outside 
of the 3D spheroid. Thus as cell number may be decreasing, the size of the spheroid may not 
be significantly changed, resulting in little difference to the measured metabolic activity. 
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To the best of my knowledge, the effect of pterostilbene on cell metabolism and cell number 
of ovarian cancer cells has not been a focus of any previous study. One study has compared 
the effect of pterostilbene on gastric carcinoma, HL-60 leukaemia and hepatocellular 
carcinoma cells at a range of concentrations up to 100µM. The pterostilbene had a dose 
dependant effect, decreasing cell viability in each of the cell types tested. For the HL-60 
leukaemia cells there was a significant decrease in cell viability  following a 10µM treatment, 
while Hep G2 cells were first significantly reduced following a 80µM treatment (Pan, Chang 
et al. 2007). This further demonstrates differences that occur between cell lines following 
pterostilbene treatment, similar to the results observed in the present study. Alosi, McDonald 
et al. (2010)) tested the effects of pterostilbene, up to a concentration of 100µM, on two 
breast cancer cell lines, MCF-7 and MDA-MB-231, grown and treated in a monolayer culture. 
Similar to the OVCAR-5 results in the current study, treatment with 50µM caused a significant 
decrease in cell proliferation. Given that monolayer based experiments typically result in a 
larger statistical decrease, strengthens the idea that SKOV-3 is affected by pterostilbene more 
than the other cell lines, as cell number was decreased at lower concentrations in a 3D culture 
compared to OVCAR-5 and previous findings which had used monolayer cultures. 
The absorbance values of the control samples following the resveratrol and pterostilbene 
treatment for both OVCAR-5 and SKOV-3 cell lines varied. A direct experiment comparing 
these two control types determined that there was no significant difference in the cells 
metabolic activity or cell number when grown with these environments. This suggests that 
the varying values are not caused by the treatments but are a result of varying cell growth 








Chapter 4: Effects of Polyphenols on the Vascular 
Endothelial Growth Factor 
4.1. Introduction 
4.1.1. Vascular Endothelial Growth Factor in Cancer 
The vascular endothelial growth factor (VEGF) is a 45kDa homodimeric glycoprotein which is 
secreted by cells to either induce vascular generation and permeability, or to stimulate 
endothelium mitosis (Ferrara, Gerber et al. 2003, Li, Wang et al. 2004). Additionally, VEGF is 
responsible for the formation of new blood vessels via angiogenesis in diseases such as 
cancer. This is critical for tumours larger than 1-2mm in size; without the blood vessels 
insufficient oxygen and nutrients would diffuse to the tumour cells and this would impact on 
cell survival and growth (Holmes and Zachary 2005). Tumour metastasis occurs as a result of 
the formation of new blood vessels, and the expression of VEGF in ascetic fluids in addition 
to the tumour fluids present. Following relocalisation of the spheroids, VEGF enables growth 
of the tumour in a new area (Figure 1.4) (Yamamoto, Konishi et al. 1997, McMahon 2000, 
Ferrara 2004, Brabletz 2012). The control for the VEGF function is known as the angiogenic 
switch; normal cells have a balance of pro-angiogenic molecules and anti-angiogenic 
molecules, in contrast to tumours where this is switched off resulting in an increase in the 
pro-angiogenic molecules, and this can lead to angiogenesis (Carmeliet and Jain 2000). 
Additionally VEGF can further promote tumour growth by inhibiting dendritic cell maturation 
or  increasing the adhesion between natural killer cells and microvessels to disrupt the 
immune response, or by upregulating the bcl-2 gene responsible to interfere with apoptosis 
(Ferrara 2005). 
To function, VEGF (VEGF-A) binds to receptors that are present on the surface of vascular 
endothelial cells, either VEGFR-1/Flt-2 or VEGFR-2/KDR. Once the growth factor has bound, 
the receptor dimerizes and becomes phosphorylated, which subsequently allows 
downstream signalling to occur (Carmeliet 2005). These receptors are believed to lead to 
different signal transduction pathways; VEGFR-1 does not lead to proliferation but does result 
in cell migration, in contrast VEGFR-2 activates the MAPK, resulting in cellular proliferation. 
Therefore, the functions of these receptors are linked as the VEGFR-2 activation benefits 
VEGFR-1 and the proliferated cells can then migrate. Following VEGFR activation, protease 
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levels for the first steps in angiogenesis are increased (Neufeld, Cohen et al. 1999). The ability 
to block these receptors could therefore be vital in cancer treatment. 
For intraperitoneal dissemination metastasis, VEGF is essential in that it facilitates the 
formation of new blood vessels. As discussed, VEGF is required for the initial tumour to 
proliferate, and once dissociated from the initial tumour, VEGF is required the EMT, MET and 
migration/disaggregation to occur and as it allows further growth in the new location, 
similarly to the initial tumour (Figure 1.4) (Brabletz 2012). 
It is suggested that VEGF levels that are present in cells are increased in tumours. Yamamoto 
et al (1997) determined that VEGF was present in 96% of carcinomas that they tested, 
compared to 33% of benign cells. This suggests that the presence of VEGF is associated with 
advanced tumours and with more ascites. Overexpression of VEGF may therefore indicate a 
poor prognosis for patients, due to increased metastasis and proliferation. VEGF can be used 
as a marker for ovarian tumours due to the increased levels in tumours. Yamamoto et al 
(1997) further demonstrated the importance of VEGF and its potential use as a marker by 
comparing the level of the growth factor prior to, and after surgical removal of a tumour, 
reporting a decrease in VEGF when the tumour was debulked. VEGF is an appealing target for 
drug therapy because it circulates in the body rather than just being confined to the tumour 
and as such could be easier to treat. This gives the potential to stop metastasis by preventing 
angiogenesis (Ferrara 2004). Drugs such as bevacizumab are currently being trialled for 
ovarian cancer treatment that act against VEGF and these can increase survival times for 
patients (Banerjee and Kaye 2013). However, these effects follow combinatorial treatments 
with cisplatin and carboplatin, so may also be limited with respect to toxicity and cell 
resistance. (Banerjee and Kaye 2013). Further research for other treatments targeting VEGF 
with a lower toxicity would be beneficial.  
4.1.2. Aims of Chapter 4 
To determine the effects of resveratrol and pterostilbene on the secretion of vascular 






3D cell culture – See chapter 2 for details. 
VEGF ELISA – See chapter 2 for details. 
4.3. Results 
4.3.1. Effect of Resveratrol and Pterostilbene on VEGF 
Production by OVCAR-5 and SKOV-3 Spheroids  
The concentrations of VEGF that was secreted into the media of the control samples for the 
OVCAR-5 spheroids were 1.58ng/mL/mg and 1.32ng/mL/mg for resveratrol and pterostilbene 
respectively. For the SKOV-3 spheroids the VEGF concentration in control media was 
1.83ng/mL/mg and 1.78ng/mL/mg for resveratrol and pterostilbene respectively. 
Following the 6 days of treatment with resveratrol, the amount of VEGF secreted by the 
spheroids did not result in a significant decrease in VEGF production, relative to the control, 
in either the OVCAR-5 or SKOV-3 cell line at any concentration tested (P ≥ 0.05, ANOVA, n=9) 
(Figure 4.1a, 4.1b). The 50µM resveratrol treatment decreased the amount of VEGF secretion 
in OVCAR-5 spheroids relative to the 10µM treatment (P<0.05, ANOVA, n=9) (Figure 4.1a). 
In contrast to the effect of resveratrol, SKOV-3 spheroids had a significant reduction in VEGF 
secretion after treatment with 50µM pterostilbene relative to the control (P<0.05, ANOVA, 
n=9) (Figure 4.2b). The 50µM pterostilbene treatment decreased the amount of VEGF 
secretion in SKOV-3 spheroids relative to the 10µM treatment (P< 0.05, ANOVA, n=9). No 









Figure 4.1. VEGF concentration present in media determined by VEGF ELISA following OVCAR-5 
cell treatment with (A) resveratrol and (B) pterostilbene at different concentrations (0µM (control), 
10µM, 30µM and 50µM). Data was normalised and average control values were 1.575ng/mL/mg and 
1.318ng/mL/mg for resveratrol and pterostilbene respectively. Data is collected from three individual 
experiments carried out in triplicate ± SEM. No statistically significant changes from the control occurred 
at any drug concentration tested. 
 
 
Figure 4.2. VEGF concentration present in media determined by VEGF ELISA following SKOV-3 cell 
treatment with (A) resveratrol and (B) pterostilbene at different concentrations (0µM (control), 10µM, 
30µM and 50µM). Data was normalised and average control values were 1.825ng/mL/mg and 
1.779ng/mL/mg for resveratrol and pterostilbene respectively. Data is collected from three individual 






The increased growth and proliferation following VEGF activation in tumours makes the VEGF 
an ideal target for drug treatment. Advanced cancers typically produce a higher level of VEGF 
compared to benign or less advanced tumours. The ability to decrease the level of VEGF could 
potentially decrease tumour proliferation and metastasis (Yamamoto, Konishi et al. 1997, 
McMahon 2000).  
As discussed in chapter 3, pterostilbene caused a decrease in cell metabolism in the SKOV-3 
spheroids after concentrations of 30µM and 50µM, and a decrease in the cell number of 
OVCAR-5 spheroids after treatment with 50µM resveratrol, and 30µM and 50µM 
pterostilbene. SKOV-3 cell number was significantly reduced by concentrations of 10µM, 
30µM and 50µM pterostilbene. The decrease in VEGF secretion, relative to the control, was 
only significant after 50µM pterostilbene in the SKOV-3 spheroids. For the remaining 
treatment samples, VEGF is functioning, and able to assist in proliferation, and therefore 
these decreasing cell numbers may be influenced by changes to pathways and signalling 
systems independent from the VEGF signalling pathway. This is consistent with a similar study 
which obtained significant decreases in the cell growth of SKOV-3 cells after treatment with 
10µM, 50µM and 100µM resveratrol but only observed a significant decrease in the VEGF 
secretion after 50µM and 100µM treatments. In contrast to the current study, there was a 
significant decrease in VEGF secretion after 50µM resveratrol. (Hogg, Chitcholtan et al. 2015). 
The current study shows a decreasing trend in VEGF secretion for OVCAR-5 after resveratrol 
treatment and SKOV-3 after pterostilbene. More replicates may produce a comparable result 
to that of Hogg, Chitcholtan et al. (2015) as the number of replicates for this study were 
relatively low.  
The present study also contrasts with the study by  Cao, Fang et al. (2004) which examined 
the effects of resveratrol on VEGF secretion in the ovarian cancer cell lines A2780/CP70 and 
OVCAR-3. VEGF secretion in A2780/CP70 cells was significantly decreased after exposure to 
25µM, 50µM and 100µM resveratrol, and in OVCAR-3 cells after exposure to 10µM 25µM, 
50µM and 100µM resveratrol. This further demonstrates the differences in the response to 
resveratrol by different ovarian cancer cell lines and the requirement for further studies to 
determine why there are differences in response and how to determine which cell line will be 
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affect more significantly with lower concentrations. Cao, Fang et al. (2004) and Hogg, 
Chitcholtan et al. (2015) determined that in all cell lines tested, 50µM and 100µM of 
resveratrol resulted in a significant decrease in VEGF secretion. Therefore the drug 
concentration range tested in the current study may be too low to elicit a significant decrease. 
The study by Cao, Fang et al. (2004) used a monolayer culture and thus caution should be 
exercised when directly comparing this study to the current one. Monolayer cultures do not 
mimic in vivo conditions as the 3D cultures do, and as such may give significant decreases at 
concentrations where there would not have been one if cultured in 3D. 
Differences between cell lines isn’t limited to ovarian cancer. A previous study which tested 
the effect of resveratrol on VEGF secretion by the melanoma cell lines A375 and YLZAZ6 
determined that although both had significantly reduced in VEGF secretion relative to the 
control, the level of reduction was more significant in the A375 spheroids (Trapp, Parmakhtiar 
et al. 2010). Therefore, the results obtained from the current study are similar to those of 
other cancers in that there is variability between different cell lines. 
To the best of my knowledge there have been limited studies which have tested the effects 
of pterostilbene on VEGF levels in cancer cells, with none focussing on ovarian cancer. One 
study which focussed on human hepatocellular carcinoma cells, HepG2, reported a decrease 
in the enzyme activities in VEGF following treatment with 50mg/kg pterostilbene. The use of 
different methodologies to assay changes in VEGF levels makes it difficult to directly compare 
the effect of pterostilbene on VEGF secretion between these two studies. However, VEGF 
secretion does appear to be following the same pattern as that observed on the SKOV-3 cells 
after pterostilbene in the present study (Pan, Chiou et al. 2009). 
VEGF drug resistance has been previously studied in cancer cells, where an extrinsic resistance 
occurred; the VEGF is successfully inhibited but the signalling required for angiogenesis and 
growth by the spheroids is still produced via the upregulation of independent pathways, such 
as IL-8, to act as a survival mechanism for the cells (Kieran, Kalluri et al. 2012). Intrinsic 
resistance, where the pathway directly responsible for the VEGF production acquires 
resistance to the anti-angiogenic drugs, has not been observed in previous studies. Thus, this 
suggests that the lack of a significant decrease in VEGF secretion in the current study are likely 
due to the drugs having little to no effect rather than due to acquired resistance in VEGF 
signalling, although further research would be required to determine this. 
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Chapter 5: Effects of Polyphenols on the Expression of 
Proteins  
5.1. Introduction  
5.1.1. Epidermal Growth Factor Receptor Family  
The Erb family consists of four different receptor tyrosine kinases: epidermal growth factor 
receptor (EGFR)/ErbB1, HER2/ErbB2, Her3/ErbB3 and Her4/ErbB4. These transmembrane 
proteins are structurally similar and consist of a cytoplasmic region with enzymatic activity 
and an extracellular ligand-binding domain. Ligand binding is specific to the various Erb 
proteins and enables specific signalling processes to occur, including signalling from 
epidermal growth factor molecules (Yarden 2001). When a signalling molecule has bound, Erb 
proteins will structurally alter to form a homodimer or heterodimer, which subsequently 
activates downstream signalling for proliferation, survival, adhesion, migration and 
differentiation (Yarden 2001, Normanno, De Luca et al. 2006).  
5.1.1.1. The Epidermal Growth Factor Receptor (EGFR)/ErbB1 
The Epidermal Growth Factor Receptor (EGFR) is a 170kD glycoprotein which when activated 
by ligand binding changes conformation to become a dimer, associating with either another 
EGFR molecule (becoming a homodimer) or another Erb protein (becoming a heterodimer). 
Following structural rearrangement, the tail region is phosphorylated on a tyrosine residue to 
activate the downstream signalling pathways: PI3K, Ras-Raf-MEK, JAK SRC and PLCγ DAG 
(Figure 5.1) The Ras-Raf-MEK mitogen pathway and the phosphotidylinositol 3 kinase (PI3K) 
pathway can both control the ability of the cell to grow. The Ras-Raf-MEK pathway affects cell 
cycle progression and motility while the PI(3)K pathway affects nutrient availability to growing 
cells, tumourigenesis and also has the ability to inhibit apoptosis, which are all hallmarks of 
cancer. The STAT and the PLCγ DAG pathways which can affect the cells ability to survive, 
differentiate and proliferate (Figure 5.1) (Herbst 2004).  
Through the regulation of the signalling pathways mentioned above, EGFR has the potential 
to play a role in the development of cancer by promoting motility and adhesion. A loss of 
regulation in these pathways can stimulate further cell growth, and thus can influence cancer. 
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Factors that can affect EGFR and the promotion of cancer include mutations, increased 
expression of binding ligands and an increase in dimerization levels (Ciardiello and Tortora 
2003). Overexpression appears to be the most significant factor due to the intensification of 
the signals for the pathways, a factor which correlates with a worse prognosis for patients, 
the formation of advanced tumours and resistance to treatments such as chemotherapy 



































































Figure 5.1. EGFR and downstream signalling pathways. Growth factors 
activate EGFR, resulting in dimerization and the phosphorylation of a 
tyrosine residue in the tail region. This leads to many downstream 
signalling pathways that are responsible for cellular survival, 
progression or growth. 
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5.1.1.2. Human Epidermal Growth Factor Receptor 
(HER2/Neu Protein) 
HER2/neu is the second member of the Erb family and is responsible for regulating cell 
proliferation. Although structurally similar to EGFR, this 185kD glycoprotein differs from other 
family members as no known ligands bind to this protein to activate signalling. Instead, HER2 
forms a heterodimer with the other Erb proteins which activates the tyrosine kinases and 
hence signalling (Serrano-Olvera, Dueñas-González et al. 2006, English, Roque et al. 2013). 
Similarly to EGFR, overexpression of this protein has been observed in a range of cancers, 
including ovarian cancer (Verri, Guglielmini et al. 2005). This causes the constitutive activation 
of tyrosine kinases, loss of regulation for the downstream signalling pathways such as Ras-
Raf-MAPK and PI(3)K-AKT,  and thus results in increased cell growth (English, Roque et al. 
2013). Overall this overexpression is believed to correlate with a worse prognosis, a higher 
recurrence frequency, decreased sensitivity to platinum chemotherapy and increased tumour 
aggression. However, there are some conflicting results suggesting this may occur more with 
certain carcinomas and may be influenced by the location of the tumour in the body; 
therefore the use of this as a prognostic factor is somewhat limited (Serrano-Olvera, Dueñas-
González et al. 2006). 
5.1.1.3. Epidermal Growth Factor Receptor/ErbB1 and 
HER2/Neu Co-Expression 
Although EGFR and HER2 can individually have significant effects on tumour formation and 
growth, when they are coexpressed more aggressive tumours can occur, resulting in a worse 
prognosis for the patient. (Normanno, De Luca et al. 2006). As EGFR is the main binding 
partner for HER2, the effect of coexpression is observed in a number of different cancers. The 
ability of HER2 to slow the dissociation of ligands from EGFR and to remain at the cell surface 
longer, before being internalised enables this interaction to prolong the signalling for the 
EGFR downstream pathways (Yarden 2001). The five year survival rate for a patient expressing 






5.1.1.4. Current Drug Targets 
The increased activation of EGFR and HER2 observed in cancer makes them an appealing 
target for drug therapy. Currently there are two ways to target EGFR. Firstly, to utilise 
monoclonal antibodies (mAbs) to target the extracellular region of the receptor. This would 
increase competitive binding and decrease the level of signalling and activation for the 
downstream pathways, resulting in inhibition and delayed growth and progression of the 
tumour (Seshacharyulu, Ponnusamy et al. 2012). Currently there are three anticancer mAbs 
in current use: cetuximab, pantitumumab and mimituzumab, however studies have 
suggested the effectiveness of these decrease when used multiple times (Baselga 2002, 
Reichert and Dhimolea 2012). Secondly, to target EGFR through the use of small molecule 
tyrosine kinase inhibitors (TKIs), such as ZD1839, which bind to the cytoplasmic side of the 
receptor in the ATP-binding pocket. This prevents phosphorylation occurring and therefore 
prevents signalling even after ligand binding (Baselga 2002, Nyati, Morgan et al. 2006).  
The ability to decrease dimerization and subsequent functioning of HER2 is a target for cancer 
research. Two drugs have previously been used to decrease HER2 activation. Trastuzumab, a 
humanised mAb IgG1 antibody has provided decreased activation when used against breast 
cancer by preventing dimerization. The similarities between breast and ovarian cancer led to 
the belief that this drug may produce similar results against ovarian cancer, however the 
effect in ovarian cancer was limited (Bookman, Darcy et al. 2003). Similarly, pertuzumab was 
of interest for its ability to interfere with the EGFR dimerization (English, Roque et al. 2013). 
Recent interest has changed to determine the effects of these drugs when used in 
combination. Pertuzumab and Trastuzumab were combined in drug therapy with the drug 
Docetaxel and tested on the HER2 activation and overall survival of patients with metastatic 
breast cancer. Observations from this study included the increase in median overall survival 
of up to 15.7 months compared to previous treatments. It is believed this increase is due to 
these drugs binding to different epitopes on the protein, resulting in increased anti-HER2 
activity.  In ovarian cancer however, further research is required to find drugs that effectively 




5.1.2. The Phosphatidylinositol (3) Kinase Protein and Signalling 
Pathway 
The Phosphatidylinositol 3 kinase (PI(3)K) protein belongs to a family which is divided into 
three different classes. The kinase that is largely associated with cancer formation is part of 
the class I family. This is further subdivided into two classes: Class IA, which is activated by 
receptors with tyrosine kinase activity, and is considered the most important for controlling 
cellular proliferation in tumour growth, and class IB, which is activated by receptors with G-
coupled proteins (Luo, Manning et al. 2003). PI(3)K is a class IA heterodimer comprised of a 
catalytic subunit, p110, and a regulatory subunit, p85. Of these, several isoforms have been 
identified, however the catalytic subunit isoform p110α is the subunit of particular interest 
for  its effects in cancer when it is overexpressed (Yuan, Sun et al. 2000).  
In cancer PI(3)K can undergo structural rearrangement in both subunits following the binding 
of a growth factor with tyrosine kinase activity (Luo, Manning et al. 2003). Without 
stimulation, the p85 subunit is bound to the p110α to prevent signalling. However, when a 
growth factor is present, the p85 will instead bind to the phosphorylated receptor tyrosine 
kinase, resulting in the relocation of the protein to the plasma membrane. This causes the 
activation site of the p110α to open, enabling the phosphorylation of the inositol ring at the 
3 position of phosphatidylinositol-4,5-bis-phosphate (PIP2) to create PIP3. PIP3 is capable of 
interacting with molecules containing a FYVE zinc finger domain (named after the proteins it 
has been found in such as Fab1, YOTB, Vac1 and EEA1) or plectstrin-homology (PH) domain. 
Specifically for the PI3K pathway, the serine-threonine kinase AKT/Protein Kinase B is bound, 
resulting in a conformational change to open the phosphorylation sites for activation. 
Although phosphorylation at the threonine 308 site partially activates the AKT, it also relies 
on phosphorylation at Serine 473 to become completely activated at which point it has the 
ability to control cell proliferation, survival, growth and other processes important in cancer 
growth, via subsequent downstream signalling (Figure 5.2) (Luo, Manning et al. 2003, Osaki, 
Oshimura et al. 2004). 
Mutation or overexpression of the PI(3)K protein can result in the activation of the signalling 
cascade leading to tumourigenesis. The PIK3CA gene encoding the p110α subunit is amplified 
in many different cancers, while the gene is mutated in only 4-12% of cases. These mutations 
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tend to occur in either the catalytic domain or the helical domain, locations believed to be 
responsible for kinase activation, due to an observed increase in AKT phosphorylation when 
these mutations are present. Additionally, cell migration has been shown to increase when 
this mutation is present (Samuels and Ericson 2006). Overall, mutations occurring in this gene 

































Figure 5.2. PI3K/AKT signalling pathway. Following binding of the growth factor. The 
heterodimer is activated causing the PI3K p85 to bind the phosphorylated tyrosine kinase 
and to release p110 to the membrane. This relocation allows p110 to open up and PIP2 to 
convert to PIP3, capable of interacting with proteins with PH domains, such as those in AKT. 
AKT becomes phosphorylated and activates downstream signalling leading to proliferation 
and cell growth through the upregulation and phosphorylation of GSK3 and prevent 
apoptosis by phosphorylating and downregulating apoptotic proteins BAD and FOXO. 
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5.1.2.1. AKT Protein and Role in Signalling  
The AKT protein which has a molecular weight of 57kD is composed of three parts: an N-
terminus containing the plectstrin-homology domain, a central kinase domain and the C-
terminal regulatory domain. There are three AKT isoforms which make up the AKT family: 
AKT1, AKT2 and AKT3, all of which act independently to one another and are encoded by 
different genes. Homology between these isoforms is high (80%), however differences have 
been determined specifically at the phosphorylation sites for activation. These differences 
occur at Threonine309 and Serine474, which are the equivalent to the AKT sites mentioned 
above. AKT is upstream of many different pathways affecting cell proliferation, specifically 
those at the transition point from the G1 to the S phase of the cell cycle (Osaki, Oshimura et 
al. 2004). In normal cells, the glycogen synthase kinase-3 (GSK-3) prevents the cell cycle from 
progressing by phosphorylating key components such as glycogen synthase or cyclin D, thus 
causing inactivation. However, in cancer cells, AKT can inhibit this action through the 
phosphorylation of the serine residue in the N-terminal domain of the GSK-3, the site 
responsible for the downstream phosphorylation and activation of signalling (Figure 5.2). 
Specifically, this affects β-catenin, a protein responsible for regulating gene transcription. Due 
to AKT inhibiting this downstream phosphorylation, β-catenin remains active and present in 
the nucleus, leading to the transcription of genes for the activation of cyclin D1, therefore 
resulting in the continuation of the cell cycle and progression (Osaki, Oshimura et al. 2004). 
Due to the role of the PI(3)K signalling pathway in cellular proliferation, during tumourigenesis 
cell cycle regulating components must be deactivated. The CDK inhibitors P21Cip1 and P27Cip2 
are both targeted by the activated AKT protein, both directly and indirectly. P21Cip1 is down-
regulated, either directly by AKT or by the GSK-3 when this is downregulated by AKT. Both the 
CDK inhibitors get phosphorylated to prevent their translocation to the nucleus where they 
can inhibit cell cycle progression (Osaki, Oshimura et al. 2004). The CDK inhibitor is also 
indirectly affected through phosphorylation of a member of the Forkhead family of 
transcription factors, the Forkhead box class O (FOXO). When AKT is activated, this 
phosphorylates the FOXO at serine/threonine residues resulting in it being removed from the 
nucleus where it would normally function to regulate the P27Kip2 (Figure 5.2)(Chang, Lee et al. 
2003, Bader, Kang et al. 2005). 
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In addition to affecting the proteins responsible for controlling the cell cycle, activated AKT 
can affect apoptosis in two ways, firstly by inhibiting procaspase-9, a significant caspase in the 
apoptotic pathway. In addition, it can phosphorylate the Bcl-2-associated death promoter 
(BAD), resulting in inhibition and therefore the lack of control for apoptosis (Osaki, Oshimura 
et al. 2004). 
In contrast to the PI(3)K, no genetic mutations in AKT have been detected, however 
overexpression/amplification has been reported (Osaki, Oshimura et al. 2004). To the best of 
my knowledge, no mutations have been detected to date. This overexpression appears to be 
isoform specific; AKT1 has not been detected to be overexpressed/amplified in any of the 
ovarian cancer tumour types examined, and AKT2 is overexpressed/amplified in 10-20% of 
cases  (Yuan, Sun et al. 2000, Osaki, Oshimura et al. 2004). Overexpression has been shown 
to  occur late in the development of ovarian cancer, specifically in stages III or IV, suggesting 
that when this change to protein function is present, the cancer is in an advanced stage and 
is more aggressive, which signifies a worse prognosis for the patient. Specifically, as the grade 
of cancer increases, the overexpression and subsequent activation of the AKT protein also 
increases (Yuan, Sun et al. 2000, Altomare and Testa 2005). For this reason, it is an ideal target 
for treatment in these later stages and grades of ovarian cancer. 
In addition to being a major part of the PI(3)K signalling pathway, AKT also has a significant 
role in the process of metastasis, where the increased expression of AKT results in a possible 
increase in metastasis. Studies have shown that the invasion stage of metastasis is increased 
due to an increase in the amount of β1 integrin present and thus an increase between β1 
integrin and collagen on the ECM, and subsequently increased MMP levels (Arboleda, Lyons 
et al. 2003). 
Overall, due to the significant pathways the AKT protein is involved in, this is an ideal protein 
to target for the prevention of further cell growth and migration. 
5.1.3 Proliferating Cell Nuclear Antigen 
The proliferating cell nuclear antigen (PCNA) is involved in DNA replication, epigenetic 
maintenance and DNA repair processes including mismatch repair, base and excision repair 
and is highly expressed in the G1-S stage of the cell cycle (Figure 1.3). This 36kDa protein was 
originally discovered approximately 30 years ago where it was determined to be an antigen 
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for an autoimmune disease. Subsequent to this another study determined this protein had a 
role in the cell cycle, and called it cyclin. It was later determined that this was the same protein 
and was renamed PCNA (Strzalka and Ziemienowicz 2011). Structurally PCNA is composed of 
3 monomers, formed by 2 domains that are joined together by a β-sheet in an antiparallel 
direction, resulting in a ring formation similar to DNA sliding clamps. This structure allows for 
the PCNA to slide along the DNA polymerase-δ during chromosomal DNA replication. 
Although overall PNCA is negatively charged, the internal ring is positively charged due the 
presence of arginines and lysines. The negatively charged DNA double helix can then slide 
through the internal ring for processing (Naryzhny 2008). 
In addition to sliding along DNA, PCNA interacts with proteins involved in the cell cycle, 
specifically cyclins and cyclin dependant kinases, and thus has an important role in 
proliferation. Specifically the cell cycles S-phase proteins cyclin A and CDK2 which are drawn 
to the PCNA to form a complex. Due to PCNA being bound to the DNA as a sliding clamp, the 
ability to bind other proteins is beneficial to proliferation as it brings the required proteins to 
the replication site (Maga and Hübscher 2003). However, cyclin A is not the only cyclin 
associated with PCNA. In contrast, cyclin D acts a regulator, capable of binding to PCNA and 
preventing association with the replication complex required (Naryzhny 2008). Regulation of 
PCNA also occurs through the p21 protein. Additional to the capability of p21 to bind CDKs at 
the N-terminal to prevent CDK-cyclin complexes forming, when present at a high level it can 
bind to PCNA at the C-terminal to inhibit DNA replication by preventing the interactions 
required for PCNA to function with the DNA polymerase δ. In cancer, the cells regulation is 
often shut down so if p21 is not active or overexpressed and therefore relocated in the cell 
where it is no longer useful, proliferation would be capable of continuing via the interaction 








5.1.4. Cyclin D and Cancer 
Cancer is the disease of uncontrolled cell growth, which makes the cell cycle an important 
aspect of this disease. As mentioned previously, the cell cycle begins in a quiescent state 
before moving to the G1 stage of the cycle. The family of cyclin D is responsible for this initial 
transition into the G1 following induction by mitogenic cycles, present only when the cell is 
required to replicate. This cyclin family consists of three different cyclins (D1, D2 and D3) and 
although there is similarity in the amino acid sequences, they are expressed differently in each 
cell type and cell line, and not all are present in each cell line (Choi, Li et al. 2012). Following 
mitogen activation, cyclin D binds to the appropriate CDKs, specifically CDK4 and CDK6, a 
complex which then relocates to the cell nucleus to become phosphorylated by the CDK-
activating kinase (CAK), enabling the subsequent phosphorylation of the retinoblastoma 
protein. The retinoblastoma protein is essential for the transition from the G1 phase to the S 
phase. In the non-phosphorylated state, this protein binds E2F, a family of transcription 
factors, preventing them from transcribing the genes required at the end of the G1 phase.  
Following phosphorylation of the retinoblastoma by the CDK-cyclin D complex, the E2F is 
released and to undergo transcription (Pines 1995, Giacinti and Giordano 2006). Cyclin D2 is 
a 34 kDa proto-oncogene which is amplified in some ovarian cancers. In addition to regulating 
the cell cycle through the retinoblastoma phosphorylation, cyclin D2 is capable of ectopic 
overexpression, which prevents the cell cycle from continuing, resulting in the cell exiting the 
cell cycle rather than continuing to undergo division and proliferation. The importance of the 
cyclin D proteins in the cell cycle therefore make it a desirable target for drug treatment, and 
this study aims to determine if there are changes in the cyclin D2 protein expression (Pines 
1995). 
5.1.5. Aims of Chapter 5 
To investigate the effects that resveratrol and pterostilbene have on the protein expression 
of Epidermal Growth Factor Receptor/ErbB1 and HER2/neu in both the phosphorylated and 
non-phosphorylated forms. Also to determine the level of protein expression of AKT and the 





3D cell culture –See chapter 2 for details. 
BCA protein Assay – See chapter 2 for details. 
Western Blotting – See chapter 2 for details. 
5.3 Results 
Protein expression was determined using western blot and densitometry, however, due to 
limited time and resources not all proteins for each cell line were imaged and due to the 
housekeeping protein, glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) only working 
for half the samples, not all were able to have densitometry carried out and therefore results 
for those proteins are based on band observation only. Due to the time restraints there was 
only one repeat (n=1) of each protein sample tested.  
5.3.1. AKT/pAKT Expression after Resveratrol and Pterostilbene 
Treatment 
Resveratrol caused an increase in AKT levels in OVCAR-5 spheroids following 10µM, 30µM 
and 50µM treatments relative to the control. 30µM and 50µM treatments decreased relative 
to the 10µM (Figure 3.5a). The level of the activated AKT, pAKT, had a large increase after 
10µM and 50µM resveratrol, increasing the densitometry ratio by 0.37 (Figure 5.3b). In SKOV-
3 spheroids, the AKT level is static in the 10µM and 30µM relative to the control but decreases 
after 50µM resveratrol. pAKT had no change from the after 10µM and 30µM resveratrol, but 
increases after 50µM resveratrol treatment (Figure 5.5). In OVCAR-5 spheroids, 50µM 
pterostilbene caused an increase in protein expression of AKT, while the other treatment 
concentrations were similar to the control (Figure 5.6). In contrast, pAKT had a decrease in 
expression following each treatment sample of pterostilbene in OVCAR-5 spheroids (Figure 
5.6). Pterostilbene treatment to the SKOV-3 spheroids resulted in an increase in AKT 
expression following 10µM and 30µM treatment, then decreased at 50µM back to a level 
similar to the control (Figure 5.7a). Although the densitometry ratio illustrates an increase in 
pAKT expression, the ration is only increased by 0.000169, suggesting no change in the 
expression of pAKT (Figure 5.7b). 
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5.3.2. Cyclin D2 Expression after Resveratrol and Pterostilbene 
Treatments 
Resveratrol caused an increase in the expression of cyclin D2 in OVCAR-5 spheroids after 
10µM and 50µM but no change after 30µM (Figure 5.3c).  In contrast, pterostilbene treatment 
resulted in a dose dependant decrease in protein expression in the OVCAR-5 spheroids, where 
expression was decreased after 30µM and 50µM pterostilbene (Figure 5.4). SKOV-3 spheroids 
after resveratrol produced similar results to the control (Figure 5.5). Densitometry illustrated 
an increase in the 10µM and 30µM pterostilbene treatments in SKOV-3 spheroids for cyclin 
D2 expression, and no obvious change from the control after 50µM treatment. However, the 
increase in densitometry ratio was only 0.00015, suggesting no change. However, the images 
obtained from the western blot suggest an increase in expression following 10µM and 30µM 
(figure 5.7c). 
5.3.3. EGFR/pEGFR Expression after Resveratrol and Pterostilbene 
Treatments 
Images for EGFR were limited to resveratrol treatment to OVCAR-5 spheroids and 
pterostilbene treatment to SKOV-3 spheroids. In the OVCAR-5 sample, a decrease in 
expression occurred after 30µM and 50µM treatment (Figure 5.4a). In contrast, SKOV-3 after 
pterostilbene resulted in an increase in the 10µM and 30µM samples (Figure 5.8a). 
The western blot for pEGFR in both samples produced a clear ladder marker, suggesting a 
successful western blot, but limited protein bands, suggesting this protein was not present in 







5.3.4. Expression of pHER2/HER2 and PCNA after Resveratrol and 
Pterostilbene treatment 
Due to limited time and resources the western blots for pHER2/HER2 and PCNA samples did 
not obtain results from all samples. Using densitometry, pHER2 in OVCAR-5 spheroids after 
pterostilbene did not change from the control in any treatment concentration tested (10µM, 
30µM or 50µM). However, in the image produced from the western blot it there appears to 
be an increase after the 30µM and 50µM treatment, illustrating the need for replicates. 
(Figure 5.4b). HER2 in OVCAR-5 spheroids after pterostilbene gave a dose dependant 
decrease in expression. (Figure 5.6). 
In SKOV-3 spheroids, an increase in PCNA expression was observed following 10µM 
treatment, and a large increase occurred following 50µM pterostilbene, observed by an 














Figure 5.3. Western blot for protein expression of (A) AKT; (B) pAKT; (C) cyclin D2 and (D) 
GAPDH in OVCAR-5 spheroids after resveratrol treatments at 0µM, 10µM, 30µM and 50µM. 
10µg of protein sample was loaded for each sample and compared to a reference protein, 









Figure 5.4. Western blot for protein expression of (A) EGFR; (B) pHER2 and (C) GAPDH in 
OVCAR-5 spheroids after resveratrol treatments at 0µM, 10µM, 30µM and 50µM. 10µg of 























Figure 5.5. Western blot of protein expression of AKT, pAKT and cyclin D2 in SKOV-3 spheroids 


















 Figure 5.6. Western blot of protein expression of AKT, pAKT, cyclin D2 and HER2 in 










Figure 5.7. Western blot of protein expression of (A) AKT; (B) pAKT; (C) cyclin D2 and (D) GAPDH in 
SKOV-3 spheroids after pterostilbene treatments at concentrations 0µM, 10µM, 30µM and 50µM). 










Figure 5.8. Western blot of protein expression of (A) EGFR; (B) PCNA and (C) GAPDH in 
SKOV-3 spheroids after pterostilbene treatments (0µM, 10µM, 30µM and 50µM). 10µg of 
protein sample was loaded for each sample and compared to a reference protein, 







The PI3K/AKT signalling pathway in cancer is important for angiogenesis, tumourigenesis and 
the inhibition of apoptosis. Therefore this is a desirable pathway to target for cancer 
treatment. Using western blot analysis, antibodies specific to AKT and pAKT-serine 473 were 
used to determine expression levels of these proteins. The changes in the expression of AKT 
and increased activation of pAKT after 10 and 50µM in OVCAR-5 spheroids after resveratrol 
treatment seems unusual as no dose dependant pattern has emerged. Due to time and 
resource constraints, the western blots were repeated once (n=1) for each protein in each 
cell line. Therefore it is difficult to conclude anything with certainty with respect to the results 
of pAKT in the OVCAR-5 spheroids after resveratrol, and an error in the western blot process 
could have resulted in the weaker band for the control. The same applies for the increase in 
pAKT after 50µM resveratrol to SKOV-3 spheroids. Further replicates would be needed to 
determine this. Following 50µM resveratrol treatment in SKOV-3 spheroids a decrease in AKT 
protein expression occurred. However, an increase was observed in the phosphorylated form, 
suggesting that after resveratrol treatment, the AKT protein became more active, and thus 
resveratrol may cause activation of AKT in the SKOV-3 cell line. This activation seems an 
unusual result and to the best of my knowledge this has not been observed in any prior study 
looking at the effects of resveratrol on AKT/pAKT in cancer. Vergara, Simeone et al. (2012) 
demonstrates AKT expression in response to resveratrol as observed in previous studies. With 
the OVCAR-3 cell line, no change was observed in AKT expression, however a decrease in the 
activation from pAKT occurred with concentrations as low as 25µM.  
Pterostilbene treatment in SKOV-3 does not have a strong impact on the expression of AKT, 
however it may prevent further activation and expression of pAKT, suggesting any anti-
cancerous effect in this cell line may be due to the ability to shut down the function of the 
AKT protein. In contrast, pAKT expression in OVCAR-5 spheroids was decreased, suggesting 
pterostilbene may be capable of exhibiting anti-cancerous traits in this cell line. To the best 
of my knowledge, many studies have focussed on resveratrol and derivatives on AKT/pAKT, 
however none of which has used pterostilbene. Overall, this suggests that the response of 
AKT/pAKT to resveratrol and pterostilbene may be cell line specific. The widening of this study 
to other cell lines would be of interest to investigate this point further. 
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The role of AKT in angiogenesis is significant as it is a downstream binding partner of VEGFR2. 
Following activation of this receptor, PI3K can bind, activating the subsequent AKT pathway, 
eventually resulting in the production of the VEGF protein due to the transcriptional 
activation in this pathway. Therefore, there is a correlation between the level of VEGF and 
AKT expression (Trinh, Tjalma et al. 2009, Tsutsui, Matsuyama et al. 2010). In the current 
study, resveratrol affected activation of AKT, where increases in protein expression of pAKT 
were observed. This could be a factor in the VEGF secretion results discussed in chapter 4, 
where no significant decreases in VEGF occurred following resveratrol treatment. The 
resveratrol treatments in both the OVCAR-5 and SKOV-3 spheroids both resulted in an 
increase in the pAKT expression, suggesting the AKT/pAKT is still able to function to activate 
the VEGF. Although non-significant, there was a decreasing trend in the VEGF secretion. It is 
possible this may be caused by resveratrol causing alterations in the Ras pathway which has 
previously been shown to have a role in VEGF production and angiogenesis. OVCAR-5 has a 
mutated Kras gene so further research into this pathway’s response to resveratrol in VEGF 
signalling may give further insight (Karar and Maity 2011). Following pterostilbene treatment, 
pAKT expression was decreased for OVCAR-5 and had no change for SKOV-3 spheroids. This 
does not correlate with the decrease in VEGF secretion observed in chapter 4 for SKOV-3 after 
pterostilbene treatment of 50µM, and therefore suggests that pterostilbene may affect the 
VEGF signalling via a different pathway. The results observed in this study contrast with a 
previous study where resveratrol caused a dose dependant decrease in activated AKT 
following treatment with 25µM, 50µM and 100µM resveratrol, which correlated to the 
decrease in VEGF (Cao, Fang et al. 2004). It is difficult to know what has caused this difference 
without further research and more replicates.  
There are many proteins involved in the regulation of the cell cycle and the resulting 
proliferation. Of particular interest in this study was cyclin D2. Following treatment with 
resveratrol in the OVCAR-5 spheroids, expression of cyclin D2 displayed a similar trend to the 
pAKT. This was to be expected due to the PI(3)K/AKT signalling pathway being responsible for 
its upregulation of cyclin D2 (Muise-Helmericks, Grimes et al. 1998). In contrast, resveratrol 
in SKOV-3 spheroids resulted in a slight decrease in the expression of cyclin D2, suggesting 
the response to resveratrol may vary between cell lines. It has been previously shown that a 
decrease in cyclin D2 can occur in the presence of active AKT, through the overexpression of 
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the FOXO Forkhead transcription factors. The study showed that these transcription factors 
reduce cyclin D2 expression and subsequently the phosphorylation of the retinoblastoma 
protein, resulting in the E2F not being released, regardless of the activation level of p27kip1 
(Schmidt, de Mattos et al. 2002). It is possible that this is occurring following exposure to 
resveratrol in the SKOV-3 spheroids, however further replicates would be required to back up 
this conclusion. Further research could examine the effects of FOXO transcription factors that 
are relevant to cyclin D2. These changes to cyclin D2 expression do not mimic the pattern 
observed in the proliferation experiments discussed in chapter 3, where significant decreases 
were observed. For this reason, more cell cycle proteins should be examined in their response 
to resveratrol to determine which proteins would make better targets to shut down the cell 
cycle, especially cyclin D1, due to the high percentage (14-59%) of ovarian cancers which have 
an increased expression of the cyclin D1 mRNA (Bali, O’Brien et al. 2004). 
The reduction in cyclin D2 expression in OVCAR-5 after pterostilbene treatment at 
concentrations of 30µM and 50µM is similar to the expression observed for pAKT. This 
suggests that pterostilbene may be affecting cyclin D2 through interruption of the PI(3)K/AKT 
signalling pathway. In addition, the level of expression also correlates with the changes to 
proliferation discussed in chapter 3, where a significant decrease occurred after treatment 
with 30µM and 50µM pterostilbene in OVCAR-5 spheroids. This suggests that pterostilbene 
may be more potent in affecting the cell cycle via cyclin D2 in OVCAR-5 spheroids. In contrast, 
there was limited change in the expression of cyclin D2 after pterostilbene treatment in 
SKOV–3 spheroids. This suggests the effect of pterostilbene on cyclin D2 may be cell line 
specific. Similarly to OVCAR-5, proliferation was significantly reduced despite the relatively 
constant levels of cyclin D2, suggesting the importance of other cell cycle regulator proteins 
and pathways. The effect of pterostilbene on cyclin in previous studies appear to be limited 
to the cyclin D1 rather than D2. 
Resveratrol treatment in OVCAR-5 spheroids led to a decrease in EGFR protein expression 
after the 30µM and 50µM treatments. Using antibodies specific for pEGFR and performing a 
western blot, the resulting images appeared to have worked due to the presence of the 
ladder, however there was little to no bands present for either cell line. This could be due to 
no pEGFR expression, or possibly a faulty western blot, as there were no repeats (n=1). 
Therefore this interpretation must be taken with caution and further replicates required to 
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determine this. Similarly, a decrease in pEGFR and limited change in EGFR expression has been 
observed in a previous study, using SKOV-3 and PA-1 ovarian carcinomas after 25µM 
resveratrol (Jeong, Cho et al. 2013). This demonstrated the anti-proliferative effect of 
resveratrol, a factor that may be responsible for the decreased proliferation observed in 
chapter 3 of the current study. A second recent study which used similar techniques as the 
present study determined the effect of resveratrol on the SKOV-3 spheroids expression of 
EGFR/pEGFR. In contrast the study by Jeong, Cho et al. (2013) a decrease in pEGFR only 
occurred following 100µM resveratrol, and a non-significant decrease occurred in the EGFR 
after resveratrol treatment (Hogg, Chitcholtan et al. 2015). Due to this studies observation 
that pEGFR is downregulated after non-physiological levels of resveratrol and at 
concentrations not tested in the present study, creates doubt that it was bands for pEGFR 
appearing in the western blot image. Further replicates are required. Similarly to OVCAR-5, 
pEGFR was not observed in the SKOV-3 spheroids after pterostilbene treatment, regardless 
of the ladder appearing in the image. The increase in EGFR however could occur due to the 
downregulation of pEGFR, however the lack of replicates and no pEGFR bands in the image 
makes this conclusion difficult to make, and again should be treated with caution.  
This study observed an increase in PCNA expression, where 50µM pterostilbene treatment in 
SKOV-3 spheroids resulted in the largest increase observed. This suggests that the role in DNA 
replication, epigenetic maintenance and DNA repair can take place, to assist in the 
proliferation of the tumour cells. This is not represented by the actual proliferative effect of 
pterostilbene, as discussed in chapter 3, where a significant decrease in cell number was 
observed after 30µM and 50µM pterostilbene. In contrast to the current study, Paul, DeCastro 
et al. (2010) observed a significant decrease in PCNA expression in human colon carcinoma 
HT-29 cells following both western blot and PCNA staining. This difference could be due to 
different cancer types, or the result in this study may not be accurately reflecting the level of 
PCNA in the SKOV-3 spheroids due to only having one repeat (n=1). 
The use of monoclonal antibodies for use in the western blot is advantageous as it only binds 
to one epitope on an antigen, creating high specificity resulting in less background staining. 
However, in this research polyclonal antibodies, where antibodies an bind multiple epitopes 
on the antigen, were used for the detection of pHER2, PCNA, and GAPDH. Results produced 
may be more accurate if a monoclonal antibody was used in future, with the exception of 
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GAPDH. Housekeeping proteins typically result in high protein levels so it is unlikely the 
polyclonal antibody had a limiting effect here. 
Although this study demonstrated decreases in cell activity, due to the bioavailability 
limitation in vivo, future studies would need to assess how resveratrol and pterostilbene 
















Chapter 6: Conclusions 
As hypothesised, both resveratrol and pterostilbene exhibited anti-cancerous properties on 
cell metabolism and cell number, however there was some cell line dependency observed. In 
contrast to what was expected, pterostilbene did not always show the most potent effect, 
specifically on the metabolic activity and cell number of OVCAR-5. Although anti-cancerous 
properties were exhibited, it is difficult to conclude what the signalling pathways were that 
were directly responsible for these changes. VEGF was not affected by resveratrol in either 
cell line and was affected only at the highest concentration of pterostilbene for the SKOV-3 
cell line. This effect may be linked with the AKT pathway after resveratrol treatment as neither 
VEGF nor pAKT had significantly decreased expression. Pterostilbene decreased the 
expression of cyclin D2 in both cell lines, however this is not enough to cause the observed 
decreases in proliferation. It was hypothesised that both resveratrol and pterostilbene would 
cause potent anti-cancerous effects on EGFR, HER2 and PCNA expression, however this was 











Chapter 7: Limitations and Future Directions 
Using a Crystal Violet assay for cellular quantification requires many washing steps which 
results in the loss of cells with each wash. Although this research obtained results 
demonstrating a decreasing trend following the drug treatments when using this assay, a 
potentially unequal number cells may be lost from the samples which could affect the results. 
If this experiment were to be carried out again, using a different cell quantification method 
may provide more representative results. One such method could be by the use of Annexin 
V, a phospholipid binding protein capable of binding to phosphatidylserine. Although 
phosphatidylserine in normal cells is present in the cytoplasmic side of the cell membrane, 
during cell death via apoptosis it becomes exposed due to structural changes of the 
membrane where it can then bind to Annexin V and fluorescently tested to determine the 
number of dead cells (Van Engeland, Nieland et al. 1998). A second option could be to use 
propidium iodide in a fluorescence assay which focuses on the proliferation in different cell 
lines and eliminates the assumption that the cancer cells die via apoptosis alone rather than 
autophagocytosis as has been observed previously in cancer cells (Opipari, Tan et al. 2004). 
Both methods are advantageous because they do not require any washing steps where 
sample cells could get lost and neither require a lot of cells to obtain results (Dengler, Schulte 
et al. 1995).  
Due to the cell line specificity in the VEGF response to resveratrol by ovarian carcinomas 
observed in the current research and prior studies, it is important that further research 
focusses on a wider range of ovarian cancer cell lines to determine how they respond. From 
there, future research could focus on determining why the cell lines react differently to the 
different concentrations of resveratrol. 
Due to the importance of the cell cycle in cellular proliferation, further study deciphering the 
effect on resveratrol and pterostilbene on a wider range of cell cycle proteins is important, 
specifically, the cyclin D proteins. Further research on cyclin D2 could focus on the FOXO 
transcription factors with resveratrol and pterostilbene to see how these may be affecting 
cyclin D2 expression. Although cyclin D1 and D2 are often expressed in ovarian cancer, there 
is more research literature examining cyclin D1. This suggests this protein may have a more 
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important role than D2 in ovarian cancer and therefore future research should consider 
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